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Breast cancer is the most common cancer and the second leading cause of cancer death 
among women. About 1 in 8 U.S. women (about 12%) will develop invasive breast cancer over 
the course of their lifetime. 
Existing methods of early detection of breast cancer include mammography and palpation, 
either by patient self-examination or clinical breast exam. Palpation is the manual detection of 
differences in tissue stiffness between breast tumors and normal breast tissue. The success of 
palpation relies on the fact that the stiffness of breast tumors is often an order of magnitude greater 
than that of normal breast tissue, i.e., breast lesions feel ‘‘hard’’ or ‘‘lumpy’’ as compared to 
normal breast tissue. A mammogram is an x-ray that allows a qualified specialist to examine the 
breast tissue for any suspicious areas. Mammography is less likely to reveal breast tumors in 
women younger than 50 years with denser breast than in older women. When a suspicious site is 
detected in the breast through a breast self-exam or on a screening mammogram, the doctor may 
request an ultrasound of the breast tissue. A breast ultrasound can provide evidence about whether 
the lump is a solid mass, a cyst filled with fluid, or a combination of the two. An invasive needle 
  
biopsy is the only diagnostic procedure that can definitely determine if the suspicious area is 
cancerous. In the clinic, 80% of women who have a breast biopsy do not have breast cancer. 
Most women with breast cancer diagnosed will have some type of surgery to remove the 
tumor. Depending on the type of breast cancer and how advanced it is, the patient might need other 
types of treatment as well, such as chemotherapy and radiation therapy. Image-guided minimally-
invasive treatment of localized breast tumor as an alternative to traditional breast surgery, such as 
high intensity focused ultrasound (HIFU) treatment, has become a subject of intensive research. 
HIFU applies extreme high temperatures to induce irreversible cell injury, tumor apoptosis and 
coagulative necrosis. Compared with conventional surgical procedures the main advantages of 
HIFU ablation lie in the fact that it is non-invasive, less scarring and less painful, allowing for 
shorter recovery time. HIFU can be guided by MRI (MRgFUS) or by conventional diagnostic 
ultrasound (USgFUS). Worldwide, thousands of patients with uterine fibroids, liver cancer, breast 
cancer, pancreatic cancer, bone tumors, and renal cancer have been treated by USgFUS. 
In this dissertation, the objective is to develop an integrated Harmonic Motion Imaging 
guided Focused Ultrasound (HMIgFUS) system as a clinical monitoring technique for breast HIFU 
with the added capability of detecting tumors for treatment planning, evaluation of tissue stiffness 
changes during HIFU ablation for treatment monitoring in real time, and assessment of thermal 
lesion sizes after treatment evaluation. A new HIFU treatment planning method was described that 
used oscillatory radiation force induced displacement amplitude variations to detect the HIFU 
focal spot before lesioning. Using this method, we were able to visualize the HMIgFUS focal 
region at variable depths. By comparing the estimated displacement profiles with lesion locations 
in pathology, we demonstrated the feasibility of using this HMI-based technique to localize the 
HIFU focal spot and predict lesion location during the planning phase. For HIFU monitoring, a 
  
HIFU lesion detection and ablation monitoring method was first developed using oscillatory 
radiation force induced displacement amplitude variations in real time. Using this method, the 
HMIgFUS focal region and lesion formation were visualized in real time at a feedback rate of 2.4 
Hz. By comparing the estimated lesion size against gross pathology, the feasibility of using 
HMIgFUS to monitor treatment and lesion formation without interruption is demonstrated. In 
order to reduce the imaging time, it is shown in this dissertation that using the steered FUS beam, 
HMI can be used to image a 2.3 times larger ROI without requiring physical movement of the 
transducer. Using steering for HMI can be used to shorten the total imaging duration without 
requiring physical movement of the transducer. For the application of breast tumor, HMI and 
HMIgFUS were optimized and applied to ex vivo breast tissue. The results showed that HMI is 
experimentally capable of mapping and differentiating stiffness in normal and abnormal breast 
tissues. HMIgFUS can also successfully generate thermal lesions on normal and pathological 
breast tissues. HMI has also been applied to post-surgical breast mastectomy specimens to mimic 
the in vivo environment. In the end, the first HMI clinical system has been built with added 
capability of GUP-based parallel beamforming. A clinical trial has been approved at Columbia 
University to image breast tumor on patient. The HMI clinical system has shown to be able to map 
fibroadenoma mass on two patients with valid HMI displacement. The study in this dissertation 
may yield an early-detection technique for breast cancer without any age discrimination and thus, 
increase the survival rate.
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 CHAPTER 1. Introduction 
1.1 Breast Cancer 
Breast cancer is the most common cancer and the second leading cause of cancer death 
among women. In 2017, approximately 252,710 women will be diagnosed with breast cancer and 
approximately 40,160 will die from the disease in the US. About 1 in 8 U.S. women (about 12.4%) 
will be diagnosed with breast cancer over the course of their lifetime. A woman’s risk of breast 
cancer nearly doubles if she has a first-degree who has been diagnosed with breast cancer. In the 
meanwhile, most breast cancer cases (85%) had no family history of breast cancer [1], which is 
why screening examination is important for women. 
 
 
Figure 1.1 Illustration - Needle biopsy of the breast. Source: http://slu.adam.com 
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1.2 Breast Cancer diagnosis 
Breast cancer typically produces no symptoms at early stages, which is why screening is 
important for early detection as when the tumor is small it is most easily treated. Breast cancer can 
begin anywhere in the breast, most commonly in the lobules, which are the milk-producing glands, 
or the ducts, the passages that drain milk from the lobules to the nipple.  
The standard diagnostic process for breast cancer often has 3 stages: clinical examination, 
imaging, and needle biopsy. The first stage involves a medical history and clinical examination, 
followed in the second stage by imaging of the breast, and finally in the last stage laboratory testing 
of the sample breast tissue obtained using a needle biopsy procedure [2]. Existing common 
methods of the first and second stage include mammography and palpation, either by patient self-
examination or clinical breast exam. Palpation is the manual detection of differences in tissue 
stiffness between breast tumors and normal breast tissue. The success of palpation relies on the 
fact that the stiffness (or Young’s modulus) of breast tumors is often an order of magnitude greater 
than that of normal breast tissue [3], i.e., breast lesions feel ‘‘hard’’ or ‘‘lumpy’’ as compared to 
normal breast tissue [4]. Most masses seen on a mammogram and most breast lumps turn out to 
be benign (not cancerous). However, to determine the extent of stage and characterize the type of 
the disease when cancer is suspected, a needle biopsy (Figure 1.2) is necessary to obtain the tissue 
for microscopic analysis. 
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1.2.1 Conventional breast cancer imaging 
Mammography is the most common and recommended method for breast cancer screening 
of women in the general population. It is also the only method of screening for breast cancer shown 
to decrease mortality [5], [6]. The ability of a mammogram to detect breast cancer may depend on 
the size of the tumor, the density of the breast tissue, and the skill of the radiologist administering 
and reading the mammogram. Mammography is less likely to reveal breast tumors in women 
younger than 50 years than in older women. This may be because younger women have denser 
breast tissue that appears white on a mammogram. Likewise, a tumor appears white on a 
mammogram, making it hard to detect. 
Therefore, mammography alone does not perform as well as mammography plus 
supplemental screening in high-risk women, particularly those with dense breasts [7]. Therefore, 
supplemental screening with MRI or ultrasound is recommended in selected high-risk 
populations.  
Figure 1.2 Illustration - Needle biopsy of the breast. Source: http://slu.adam.com 
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Ultrasound is useful for looking at some breast changes, such as lumps (especially those 
that can be felt but not seen on a mammogram) or changes in women with dense breast tissue. It 
also can be used to look at a change that was seen on a mammogram. It is especially useful to tell 
the difference between fluid-filled cysts (which are very unlikely to be cancer) and solid masses 
(which might need further testing to be sure they're not cancer). However, ultrasound B-mode 
alone had the highest false-negative rate compared with mammography and MR [8].  
Breast MRI in high-risk women has been shown to have higher sensitivity than 
mammography, and the combination of mammography and MRI has the highest sensitivity. 
Screening MR imaging had a higher biopsy rate but helped detect more cancers than either 
mammography or ultrasound B-mode [9].  
In addition, the conflict of sensitivity versus specificity also matters. Most of the current 
methods are highly sensitive yet lack specificity, resulting in an alarming number of false-positive 
cases. Consequently, the increased false-positive results also increase the rate of unnecessary 
biopsies [2]. Therefore, improved methods of differential diagnosis based on quantitative measures 
of elasticity have been gaining support and interest for clinical utilization. 
 
1.2.2 Breast elasticity imaging 
Ultrasound elasticity imaging is used in addition to traditional B-mode ultrasound as a tool 
for differential diagnosis between normal and tumor in human breast based on tissue stiffness as 
it provides information not only on morphology but also on tissue elasticity. Qualitative and 
quantitative tissue strain analyses using acoustic radiation force impulse imaging (ARFI) 
technology has been developed for the diagnosis of breast masses [4], [10], [11]. The response of 
tissue to the acoustic radiation force is tracked as tissue displacement, which has been found to be 
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correlated with local stiffness of the tissue. Vibro-acoustic tissue mammography is also a radiation 
force-based method, uses focused ultrasound to vibrate tissue at frequency (kHz) and utilizes the 
resulting response to produce images that are related to the hardness of the tissue [12], [13]. 
Supersonic shear imaging (SSI) utilizes a very fast (5000 frames/s) acquisition sequence to capture 
the propagation of shear waves [14] that provide information of the local viscoelastic properties 
[15], [16].  
 
1.3 Breast Cancer treatment 
1.3.1 Conventional breast cancer treatment 
  
Once diagnosed, there are several ways to treat breast cancer, depending on its type and 
stage. Some treatments are local, meaning they treat the tumor without affecting the rest of the 
body. Types of local therapy used for breast cancer include surgery and radiation therapy. Drugs 
used to treat breast cancer are considered systemic therapies because they can reach cancer cells 
Figure 1.3 Illustration – Lumpectomy (left) and mastectomy (right). Prior to surgery, a radiologist 
often first marks the lump with a wire, making it easier for the surgeon to find. Source: 
http://slu.adam.com 
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almost anywhere in the body. They can be given by mouth or put directly into the bloodstream. 
Depending on the type of breast cancer, different types of drug treatment might be used, including 
chemotherapy, hormone therapy and targeted therapy. 
Most women with breast cancer will have some type of surgery to remove the tumor. Breast 
conserving surgery, also called lumpectomy (Figure 1.3(left)), only remove the part of the breast 
containing the cancer. The goal is to remove the cancer as well as some surrounding normal tissue. 
The other type of surgery, mastectomy (Figure 1.3(right)), removes the entire breast, including all 
of the breast tissue and sometimes other nearby tissues. Modified radical mastectomy includes 
removal of the entire breast, plus a full axillary lymph node dissection. Some women may also get 
a double mastectomy, in which both breasts are removed [1].  
 
1.3.2 Noninvasive and minimally invasive cancer therapy 
However, open surgery has been linked to significant risk of morbidity and mortality. 
Despite the surgical risk involved and the fact that the vast majority of breast cancers at diagnosis 
are non-metastatic, 94% of the patients still undergo surgery (58% lumpectomy and 36% 
mastectomy) [17], including in the case of a benign mass, with several risks and prolonged 
recovery periods. In the meanwhile, breast conservation or lumpectomy is dependent on clear 
margins, defined as no tumor cells visible on ink on the resected specimen according to American 
Society for Radiation Oncology (ASTRO) guidelines [18]. However, during surgery the surgeon 
is unable to visualize the tumor to aid in determining clear margins. This lack of intraoperative 
target definition results in high rates of reoperation to excise residual tumor. There is a clinical 
need to develop minimally invasive ablative techniques to define better the target and tumor 
margins during treatment [19]. 
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Image-guided minimally-invasive treatment of localized breast tumor has become a subject 
of intensive research and several studies have assessed the feasibility of minimally-invasive breast 
tumor ablation techniques, such as radiofrequency ablation (RFA), cryo-ablation and high intensity 
focused ultrasound (HIFU) ablation [20]. Minimally-invasive treatment applies extreme 
temperatures, either high or low, to induce irreversible cell injury, tumor apoptosis and coagulative 
necrosis [21]. Compared with conventional surgical procedures the main advantages of minimally-
invasive ablation lie in the fact that they are less invasive, less scarring and less painful, allowing 
for shorter recovery time [22]. With the widespread use of screening examination and improved 
patient education, smaller invasive breast tumors and in situ cancers are being identified more 
often for minimally-invasive treatment. RFA has been used as a local therapy to treat early stage 
breast carcinomas [23]–[25] and elderly patients with inoperable breast cancer [26]. However, as 
soon as the RFA treatment starts, the region of the targeted lesion becomes invisible or masked by 
a shadow in ultrasound guided images. Therefore, it is difficult to monitor during the RFA 
procedure and even more difficult to control it [27]. A completely non-invasive technique on the 
rise is HIFU. During HIFU, the ultrasound beam is transmitted and focused into a small target 
volume to reach high focal power levels, resulting in temperature elevations causing cell damage 
in short duration. HIFU can be guided by MRI (MRgFUS) or by conventional diagnostic 
ultrasound (USgFUS). Worldwide, thousands of patients with uterine fibroids, liver cancer, breast 
cancer, pancreatic cancer, bone tumors, and renal cancer have been treated by USgFUS [20]. 
 
1.3.3 High Intensity Focused Ultrasound for breast 
The breast is ideally suited for HIFU therapy due to its superficial position, with no 
intervening vital structures [28]. HIFU was first investigated as a non-invasive therapeutic 
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technique in the 1940s to thermally coagulate tissue at the focus to produce thermal lesions in 
living animals [29]. The HIFU beam is finely focused on a small region of the tissue and produces 
rapid and intense heating. Over the past several decades, HIFU has been increasingly explored as 
an extracorporeal modality to ablate tumors in cancer treatment, but is only recently beginning to 
emerge as a vital alternative to conventional therapies [30], [31]. Numerous studies and clinical 
trials have used HIFU to treat local diseases in organs such as the thyroid, prostate, breast, pancreas 
and liver [32]–[36]. The clinical translation and accessibility of HIFU relies heavily on improving 
its treatment monitoring. 
HIFU is an entirely non-invasive technique which focuses the ultrasound beam onto a small 
target volume to reach high focal power, resulting in temperature elevations causing coagulative 
necrosis in the target while surrounding structures are spared. Since the ultrasound wave penetrates 
through soft tissue without any surgical incision nor needle insertion, there are no damages to the 
skin or underlying tissues. Acoustic energy can induce temperature elevations at the focal spot in 
a few seconds and simultaneously induce cellular damage and vascular destruction in normal and 
tumor tissues [37]. Because of the steep thermal gradients involved, the boundaries of the 
ultrasound-treated volumes can be closely spaced until the entire target is covered.  
HIFU has also been used to ablate early stage malignant breast tumors in elderly patients 
who are not surgical candidates. Huber et al [38] used MRI-guided HIFU to treat a 56-year-old 
patient with breast cancer. Post-procedural tissue pathological examination indicated that HIFU 
induced lethal and sub-lethal tumor ablation without damage to the surrounding healthy tissue or 
systemic effects. In 2003, Wu et al. [39] reported the first clinical trial exploring the efficacy and 
safety of HIFU in the treatment of patients with breast cancer in China. The results showed that no 
severe side effects were observed in the HIFU-treated patients. Pathological findings revealed that 
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HIFU-treated tumor cells underwent complete coagulative necrosis, and tumor vasculature was 
severely damaged. In 2007, Furusawa et al. [40] reported a follow-up study of 21 patients who 
underwent MRI-guided HIFU treatment. After an average of 14 months, one case had local 
recurrence, but no evidence of recurrence was detected in the remaining 20 (95%) patients. HIFU 
has then been applied to treat solid breast tumors in the past decade or so. 
Recently, the use of ultrasound has been shown to have potential in cancer immuno-therapy. 
In addition to direct destruction of the primary tumor, HIFU thermos ablation may elicit long-term 
systemic host anti-tumor immunity [41]–[43]. Based on many pre-clinical and clinical studies, 
different possible mechanisms are suggested to explain the positive effect of anti-cancer immune 
response following focused ultrasound treatment, although clinical significance of this HIFU-
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 CHAPTER 2. Background and significance 
2.1 Harmonic Motion Imaging 
2.1.1 Tissue elasticity imaging 
Mechanical properties of tumor tissues are known to differ from the surrounding tissues, 
as indicated by the use of palpation in the clinic as a first step diagnostic tool. Elasticity imaging 
is a medical imaging technology that maps the elastic properties of soft tissue providing diagnostic 
information about the presence or status of disease. Differences in Young’s moduli are the basis 
for the investigation of elasticity imaging modalities that provide information about the stiffness 
of tissue.  
In the field of ultrasound, Jonathan Ophir et al. introduced elastography as a new method 
for quantitative imaging of strain and elastic modulus distributions in soft tissues based on external 
tissue compression [46]. Cross-correlation techniques were used on radiofrequency (RF) 
ultrasonic signals to estimate the displacement and strain in the tissue resulting from the 
compression. By measuring the stresses applied by the compressing device, the strain profile can 
then be converted to an elastic modulus profile. In 1998, Krouskop et al. [47] estimated vibration 
motion amplitudes and related them to estimates of elastic modulus by measuring the Doppler 
shifts of ultrasonic tone bursts.  
Remote application of the mechanical stimuli, such as radiation force, was introduced in 
the late 1990s to overcome the shortcomings of an external excitation.  A radiation force based 
ultrasound method, Vibro-Acoustic Spectrography, was presented for imaging the acoustic 
response of a material to mechanical excitation by Fatemi et al. [48]. Radiation force was generated 
by a two-element confocal ultrasound annular array driven by two continuous wave sources at 
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frequencies equal to 𝜔" and 𝜔# = 	𝜔" +	∆𝜔, where these frequencies are very close to the central 
frequency of the elements, and ∆𝜔 is much smaller than the center point. The low-frequency force 
on a target at the focal point can be expressed by 𝐹"(𝑡) = 	𝑑- ∬ < 𝐸12345(𝑡, 𝑥, 𝑦) >: 𝑑𝑥𝑑𝑦; = 𝐶𝑑-cos	(∆𝜔𝑡)                                    (2.1) 
where 𝐶 is a constant, S is the area over which 𝐸12345 the total energy density in the focal plane, 
and <>: indicates a short-term time average. The sound field resulting from object vibrations at 
each position is received by a hydrophone and recorded. Nightingale et al. [4] developed a method 
of acoustic remote palpation using focused ultrasound is used to apply localized radiation force 
within tissue, and the resulting tissue displacements are mapped using ultrasonic correlation-based 
methods. In this study, the radiation force is given by  
                        F = 	 (∏𝑎 +	∏ 𝑠 −	∫ 𝛾𝑐𝑜𝑠𝜃𝑟	𝑑𝑟	𝑑𝜃)〈𝐸〉                                                              (2.2) 
where ∏𝑎 is the total power absorbed by the target is, ∏𝑠 is the total power scattered by the target, 𝛾 is the magnitude of the scattered intensity, 𝜃 is the scattering angle, 𝑟	𝑑𝑟	𝑑𝜃 is an area element 
of the projection of the target onto the axial/lateral plane, and 〈𝐸〉 is the temporal average energy 
density of the propagating acoustic wave. The tissue displacements are inversely proportional to 
the stiffness of the tissue, and thus a stiffer region of tissue exhibits smaller displacements than a 
more compliant region.  Localized Harmonic Motion Imaging was developed taking advantages 
of localized oscillatory harmonic motion resulting from the harmonic radiation force produced by 
two focused ultrasound transducer elements with overlapping beams oscillating at distinct 
frequencies [49]. Different from Vibro-Acoustic Spectrography using an external hydrophone for 
detection, Localized Harmonic Motion Imaging use a separate ultrasound beam to probe the 
induced tissue motion avoid the artefacts. In addition, the use of ultrasound to detect the motion 
  12 
 
using cross-correlation techniques successfully decoupled ultrasound attenuation effects from the 
mechanical effects in different tissues.  
Ultrasound elasticity imaging has been further developed and refined to enable quantitative 
assessments of tissue stiffness. Supersonic Shear Imaging (SSI) was first introduced by Bercoff et 
al. [50] as a new ultrasound-based technique for real-time visualization of soft tissue viscoelastic 
properties. Relaying on mechanical vibration generated by ultrasonic focused beams, SSI proposed 
to create such a source moving at a supersonic speed. These waves propagate through the medium 
and are progressively distorted by tissue heterogeneities. Using ultrafast scanner prototype (5000 
frames/s), SSI was able to image (5000 frames/s) the propagation of the resulting shear waves. As 
measurement of the shear wave speed results in qualitative and quantitative estimates of tissue 
elasticity, an elasticity maps were obtained in heterogeneous medium containing hard inclusions 
and on healthy breasts. To date, the following commercially available systems use shear wave 
elastography technology: FibroScanTM (Echosens, Paris, France), Virtual TouchTM Imaging 
Quantification (VTIQ/ARFI) by Siemens, Shear WaveTM Elastography by SuperSonic Imagine 
(SSI), Shear Wave Elastography by Philips, Acoustic Structure QuantificationTM (ASQ) by 
Toshiba, and 2D-SWE by GE Healthcare [51]–[53]. 
In elasticity imaging, local tissue characters are determined by measuring local 
displacements that occur during global tissue compression or acoustic radiation forced induced 
vibration (Figure 2.1). The magnitude of the tissue displacement is inversely proportional to the 
local stiffness of the tissue. Therefore, a relative stiffness map can be generated using ultrasound-
based elasticity imaging. 
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Figure 2.1 Ultrasound-based elasticity imaging methods can be categorized by the excitation 
source used to deform soft tissue. As presented herein, acoustic radiation force-based elasticity 
imaging methods can be further classified according to the duration of the applied acoustic 
radiation force excitation. 
 
2.1.2 Harmonic Motion Imaging 
The harmonic motion imaging (HMI) technique using single focused ultrasound transducer 
was first described our group [54]. Using a single focused ultrasound transducer as opposed to two 
separate elements [49] has shown the advantage of sustaining the application of the radiation force 
at a constant, stable focus within the tissue region. The displacement amplitudes are measured at 
the location of the applied force using a pulse-echo transducer.  A finite-element mode (FEM) 
study was presented with an experimental validation [55] to show that HMI can be used as a 
reliable tumor-mapping technique based on the tumor’s distinct stiffness comparing with its 
surrounding tissue. On the other hand, HMI has shown the feasibly for attenuation measurements 
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for measuring elastic properties non-invasively by using internal indentation [57]. The HMI elastic 
modulus 𝐸NOPwas defined as the ratio of the applied force to the axial strain measured. Initial 
feasibility was also shown very good correlation and agreement was found between the measured 
Young’s modulus and the HMI modulus in the numerical study and on polyacrylamide gels. 
 
2.2 Harmonic Motion Imaging guided Focused Ultrasound 
2.2.1 HIFU monitoring  
Over the past 70 years, researchers have investigated the potential of utilizing high intensity 
focused ultrasound (HIFU) as a minimally, or non- invasive, cancer treatment modality. Currently, 
MRI and sonography are being used for guidance and monitoring of HIFU therapy. Both MR-
guided HIFU (MRgFUS) and ultrasound-guided HIFU (USgFUS) methods have their advantages 
and disadvantages.  
It has been well known that most endogenous MRI- sensitive parameters are temperature 
sensitive. Based on the temperature dependence of T1 relaxation time in tissue, T1 is proportional 
to 1/T over a small range of temperatures, MRI was shown to be compatible with focused 
ultrasound treatment [58], [59]. MRI-based techniques can provide reliable functional and 
anatomical information during HIFU treatment can currently be provided only by using MRI-
based techniques. In one of its first breast cancer clinical trials, nine patients (eleven fibroadenomas) 
were treated over two hours for 2-cm and 45 min for 1-cm lesion sizes with an average temperature 
rise of up to 45.9 °C. Common side-effects, such as skin burn or swelling following the treatment, 
were not observed six months after treatment and no sign of tumor re-growth in the same treated 
region was detected 3-4 years following treatment [60]. Despite its exquisite imaging quality and 
thermometry feedback, MRIgFUS incurs low temporal resolution resulting in lengthy procedures 
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(up to 3 hours for uterine fibroid HIFU ablation [61]) together with co-registration challenges, 
restrictions in the patient pool and large physical space requirements. MRI has also been shown 
particularly challenging in the breast. Proton-resonance frequency shift (PRFS)-based MRT is the 
most widely used method during MR-guided thermal therapies. Unfortunately, this technique does 
not work for protons in fat molecules. Fat-suppression techniques therefore have been employed 
during PRFS-based MR thermometry in fat-containing tissues. However, during breast tumor 
ablation, preferably both the temperature of the tumor and surrounding adipose tissue should be 
measured. Monitoring of temperatures in fat tissue is important to reduce the risk of skin burns 
and also when treating a margin around the tumor. Furthermore, a second problem related to the 
use of PRFS-based MRT for breast thermometry has been recently raised. This problem is the 
occurrence of temperature-induced susceptibility changes of fat, which can introduce significant 
errors in PRFS-based MR thermometry and may cause inaccurate temperature measurements in 
the fibroglandular breast tissue during MR-HIFU ablation [62]. An additional problem is caused 
by respiration. The fact that the air volume inside the lungs changes over the respiratory cycle 
gives rise to time-varying changes in the magnetic field inside the breasts that can cause 
considerable temperature errors in PRFS-based MR thermometry [63], [64]. As a result, despite 
the promise shown in studies over the past 15 years, breast HIFU remains unavailable to patients 
unlike other breast ablative procedures in the clinic. 
In addition, thermometry only provides temperature elevation (or, thermal dose) but not 
the coagulation onset, which is most important for informing lesioning and reported to occur at 
distinct temperatures across organs or even within the same organ. The thermal dose for changing 
temperature exposure was calculated using the technique suggested by Sapareto and Dewey. 
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Numerical integration was used to calculate the time that would yield an equivalent thermal dose 
at a reference temperature for different temperature profiles, as given by 
                                            𝑡QR = ∑ 𝑅(QRU:V)∆𝑡WX1YZ45WX[                                                     (2.3) 
where 𝑡QR is the equivalent time at 43 °C, and Tt is the average temperature during ∆𝑡. The value 
of R was 0.25 for temperatures lower than 43 °C and 0.5 for temperatures higher than 43 °C. These 
values were chosen because they are the most common values measured [65]. However, studies 
have shown that different tissues respond differently to heat exposure requiring different thermal 
doses for ablation [66].  
Therefore, elasticity-based HIFU monitoring aims at detecting and tracking the relative 
changes in tissue elasticity upon formation of thermal lesion have been developed and 
implemented. Magnetic resonance elastography (MRE) has shown to be capable of quantitatively 
estimating the differences in shear modulus between the HIFU lesion and the untreated tissue, 
indicating that the ablated regions were stiffer than the untreated ones [67]. In addition to MRE, 
many ultrasound-based elasticity imaging studies also investigated the Young’s modulus of HIFU 
lesions for comparative analyses with mechanical testing. Past studies include, but are not limited 
to, elastography for HIFU treatment [68]–[75]. 
 
2.2.2 HMIgFUS 
In prior work by our group, a theoretical framework of HMIgFUS was built, comprising a 
customized nonlinear wave propagation model, a finite-element (FE) analysis module and an 
image-formation model to assess the fundamental performance of HMIgFUS in detecting HIFU 
lesions based on the change in tissue apparent elasticity [76]. For a lesion-to-background Young’s 
modulus ratio of 3, 6 and 9, the FE and estimated HMI displacement ratios were equal to 1.83, 
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3.69 and 5.39 and 1.65, 3.19 and 4.59, respectively. In addition, moderate agreement in lesion size 
growth was found in both simulations (16.2, 73.1 and 334.7 mm2) and experiments (26.2, 94.2 and 
206.2 mm2). Therefore, the feasibility of HMIgFUS for HIFU lesion detection based on the 
underlying tissue elasticity changes was verified through the developed theoretical framework, i.e., 
validation of the fundamental performance of the HMIgFUS system for lesion detection, 
localization and quantification, was demonstrated both theoretically and ex vivo. HMIgFUS was 
performed to investigate both elastic and acoustics-independent viscoelastic tissue changes using 
the Harmonic Motion Imaging (HMI) displacement, axial compressive strain and change in 
relative phase shift during high energy HIFU treatment with tissue boiling [77], [78]. HMIgFUS 
had been applied in a transgenic breast cancer mouse model to monitor changes in mechanical 
properties of tissues during thermal therapy in vivo [79]. Results from two mice with eight lesions 
formed in each mouse (16 lesions total) showed that the average peak-to-peak displacement 
amplitude before and after lesion formation was respectively equal to 17.34 ± 1.34 µm and 10.98 
± 1.82 µm (p < 0.001). Cell death was also confirmed by hematoxylin and eosin (H&E) histology. 
HMIgFUS was also applied for abdominal tumor detection in a transgenic mouse model of 
pancreatic cancer [80], [81]. HMI monitoring of HIFU ablation found significant decrease in the 
peak-to-peak HMI displacements before and after HIFU ablation with a reduction rate ranging 
from 15.8% to 57.0%. The formation of thermal lesions after HIFU exposure was confirmed by 
histological analysis.  
 
2.3 Overview and significance 
The objective is to develop an integrated HMIgFUS system as a clinical monitoring 
technique for breast HIFU with the added capability of detecting tumors for treatment planning, 
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evaluation of tissue stiffness changes during HIFU ablation for treatment monitoring in real-time, 
and assessment of thermal lesion sizes after treatment evaluation. In achieving the goal, the 
HMIgFUS system for both imaging and real-time treatment monitoring will be developed and 
evaluated in ex vivo post-surgical breast tissue specimens. Finally, a clinical HMI system will be 
developed for initial feasibility testing in patients.  
In order to develop, test and optimize and a HMIgFUS system for breast tumor 
characterization and ablation monitoring, there is a need to localize the HIFU focal spot within the 
tissue in the treatment planning stage. A real-time lesion formation monitoring method is also 
essential for treatment monitoring.  Ex vivo study on human breast tumor is needed for feasibility 
test and system optimization before the clinical trial of HMI in patents. The dissertation is thus 
separated into five specific chapters: HIFU focal spot localization, real-time lesion quantification, 
HMI with electronic beam steering, HMIgFUS for ex vivo breast tumor characterization and 
treatment monitoring, clinical HMI initial results.  
 
Chapter 3: HMI is capable of HIFU focal spot localization in 1D and 2D 
The objective of this chapter is to develop and test the feasibility of using the HMIgFUS 
method to localize the focus of the HIFU beam. To our knowledge, this is the first radiation-force-
based all-ultrasound elasticity imaging method designed for focal spot localization, which is also 
robust to temperature limit and motion artifact. In this chapter, both 1D and 2D HMI systems were 
used to assess the feasibility of focal spot localization on tissue-mimicking phantom, in vitro liver, 
and ex vivo human breast specimens. The focal spots detected by HMI were validated with gross 
histology. 
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Chapter 4: Real-time lesion quantification in HMIgFUS 
The objective of this chapter is first to develop a HMIgFUS-based lesion quantification 
method to detect and quantify HIFU-induced thermal lesions. We have also demonstrated the 
accuracy as well as reproducibility of the lesion quantification method through gross pathology 
validation in vitro and in vivo. We have shown the implementation of a lesion quantification 
method for on-line processing by incorporating a GPU-based, sparse-matrix algorithm to achieve 
lesion development monitoring during HMIgFUS treatment in real time. 
 
Chapter 5: Focused ultrasound steering for Harmonic Motion Imaging (HMI) 
The objective of this chapter is to develop and demonstrate initial feasibility of electronic 
steering of focused ultrasound for HMI using a HIFU phased array to facilitate the scanning 
process. The main interest of the electronic steering compared to the mechanical movement arises 
from the dramatically shorter time required to move the focal spot. In this chapter, we have 
demonstrated that HMI can be used to image a 2.3 times larger region of interest without requiring 
physical movement of the transducer using the steered focused ultrasound beam. Using electronic 
steering for HMI can be used to shorten the total imaging duration without requiring physical 
movement of the transducer. 
 
Chapter 6:  HMIgFUS is capable of human breast tumor characterization and treatment 
monitoring ex vivo  
The overall objective of this chapter is to investigate the potential complementary role of 
HMI, which can provide measurements of the locally generated mechanical responses and inherent 
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mechanical properties of breast tissues ex vivo. This chapter has demonstrated the initial feasibility 
of HMI and HMIgFUS on both small piece and large piece ex vivo human mastectomy specimens.  
 
Chapter 7:  Clinical HMI in patients 
In this chapter, the goal is to develop and build a clinical HMI system with parallel 
beamforming and automatic rater scan using a robotic arm. The HMI clinical system consisted of 
3 parts: 1) an ultrasound imaging research system with a designated host PC for system control, 
real-time display and data acquisition; 2) a FUS transducer and a phased array imaging probe for 
imaging and motion tracking; 3) a robotic arm for automatic raster scan. Finally, the optimized 
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 CHAPTER 3. Harmonic Motion Imaging (HMI) for focused 
ultrasound focal spot localization  
3.1 Introduction 
Treatment planning constitutes one of the most critical aspects of HIFU treatment. Correct 
placement of HIFU beam and securing clear acoustic path to the target tissue is critical in order to 
avoid unnecessary thermal damage on normal tissues. The targeting step is essential because the 
apparent focal spot can be shifted from the geometric focus due to phase aberrations caused by 
tissue inhomogeneity [82]. To this end, many researchers have been developing techniques and 
methods for HIFU treatment planning. As of now, HIFU treatment planning and real-time 
monitoring are performed by two major imaging modalities, magnetic resonance imaging (MRI) 
and ultrasound imaging. During the planning stage of MR-guided focused ultrasound (MRgFUS) 
treatment, a small temperature increment is generated at the focal spot. MR thermometry is used 
to generate a quantitative temperature map of tissues and detects the focal spot with a small 
temperature elevation as low as 1˚C [83].MR acoustic radiation force imaging (MR-ARFI) has 
previously been proposed to locate the beam using tissue displacement map at low intensities to 
avoid heat deposition in the target during planning [84]–[86]. Despite its advantages, MRgFUS 
still relies on a high-cost hybrid system and has relatively low temporal resolution. Compared to 
MRI, ultrasound itself is a low-cost imaging modality offering several advantages, including high 
temporal resolution and lower compatibility requirements. Conventional B-mode has been found 
to be capable of detecting hyperechoic regions due to cavitation and/or boiling at the focus but 
these phenomena are by definition random and unreliable especially after HIFU cessation [87].  
Ultrasound-based temperature mapping relies on the temperature dependence of the speed of 
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sound in tissues, which increases with temperature between 37˚C and 50˚C in non-fatty tissues 
[88]–[90]. However, the limitation of ultrasound-based temperature measurements lies in the fact 
that the linear relationship between the speed of sound and temperature is no longer valid at 
temperatures above 50˚C or higher.  Based on RF data, Vaezy et al. aimed at targeting by 
monitoring the focal RF signal increase immediately and showed that the focal RF amplitude 
increased immediately after HIFU started at subablative intensities [91]. However, it may lose 
accuracy for in vivo application where motion disturbance is much more significant on a pixel-to-
pixel basis. 
Instead of estimating temperatures or quantification of the backscatter RF signals, 
Harmonic Motion Imaging guided Focused Ultrasound (HMIgFUS) monitors the localized 
displacement at the focus as an indicator of the HIFU focal zone placement. HMIgFUS is a 
dynamic, all-ultrasound based system for both ablation and imaging, which utilizes a HIFU 
transducer by emitting an amplitude-modulated (AM) beam to simultaneously thermally ablate 
and induce a stable oscillatory tissue displacement at its focal zone. The oscillatory response is 
then estimated by a cross-correlation-based motion tracking technique on the RF signal collected 
by a confocally-aligned diagnostic transducer. It is based on the radiation force to induce vibration 
at the focal zone for the detection of localized stiffness changes [92].  
The main objective in this chapter is to study the feasibility of using the HMIgFUS method 
to localize the focus of the HIFU beam. To our knowledge, this is the first radiation force based 
all-ultrasound elastography method designed for focal spot localization, which is also robust to 
temperature limit and motion artifact.  In this chapter, we will use a 1D and 2D based system to 
assess the feasibility of focal spot localization on phantom, in vitro liver, and ex vivo human breast 
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3.2.1 HIFU focal spot localization experimental materials 
3.2.1.1 Tissue-mimicking phantom preparation 
Phantom experiments were conducted to verify the efficacy of the proposed method. 
Gelatin powder (Gelatin 50 bloom, MP Biomedicals, Irvine, CA, USA) was used to construct the 
tissue mimicking phantoms. Three homogeneous phantoms with elastic modulus of 10 kPa were 
constructed. The concentration of gelatin powder was 50.7g/L yielding a stiffness of 10 kPa. 
Phantom preparation was completed using the following steps [93]: 1) gelatin powder was 
hydrated in a solution of deionized water and isopropanol and heated above its gelling point to 
disperse the colloid, clarify the solution, and release trapped gasses; 2) the mixture was then placed 
into an ice water bath for the purpose of cooling. While the gel solution is liquid, agar powder was 
added to increase the absorption and the scattering. Note that the agar melted only at temperatures 
higher than 80˚C; thus, it did not significantly contribute to the increase of the phantom stiffness. 
The mixture was constantly stirred until the temperature decreased to 25˚C; 3) and the solution 
was poured into a mold carefully and placed in a refrigerator overnight.  
3.2.1.2 In vitro and ex vivo specimen preparation  
Experiments were performed in 9 in vitro canine liver specimens on three to six different 
ablation locations (dependent on the size of the liver) within each specimen. Liver was chosen for 
the experiment because of its relatively homogenous structure and allowing lesions to be optical 
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contrast in gross pathology. Tissue samples were degassed in phosphate buffered saline (PBS) for 
1 hour at room temperature prior to each experiment. In experiments, each specimen was immersed 
in degassed PBS and fixed on an acoustic absorber using metallic needles.  
 
3.2.2 HIFU focal spot localization in 1D 
The 1D HMI system was comprised of a 4.755-MHz HIFU transducer (Riverside Research 
Institute, New York, NY, USA) and a 7.5 MHz single-element transducer (Olympus NDT Inc., 
Waltham, MA, USA).  The HIFU transducer (outer diameter = 80 mm, inner diameter = 16.5 mm, 
focal depth = 90 mm) was used to generate the acoustic force using a low frequency amplitude-
modulated RF signal. The -6 dB pressure focal region has an ellipsoidal shape with 7.7 mm in the 
axial direction and 0.67 mm in the lateral direction.  A function generator (33120A, Hewlett-
Packard, Palo Alto, CA, USA) was used to generate a low frequency amplitude modulation 
waveform at 25 Hz. A second function generator (33220A, Agilent Technologies Inc., Santa Clara, 
CA, USA) was used to construct the continuous carrier signal at 4.755 MHz with 200% amplitude 
modulation using the input from the first function generator. The single-element transducer was 
driven by a pulser/receiver (5072PR, Olympus, Waltham, MA, USA) with a frame rate at 1000 
Hz. RF signals within 10 cm from the transducer surface were recorded using a data acquisition 
unit (Gage applied, Lockport, IL) at a sampling frequency of 100 MHz. The received RF signals 
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from the pulser/receiver were filtered using an analog band-pass filter (Reactel Inc., Gaithersburg, 
Maryland, USA) with cutoff frequencies of fc1 = 5.84 MHz and fc2 = 8.66 MHz (Figure 3.1). 
 
In this study, a short, continuous AM HIFU wave was used for localizing the focused 
ultrasound beam. A 1-s duration was sufficient to obtain stabilized HMI displacement while short 
enough to avoid significant temperature rise [76]. 
One-dimensional cross-correlation [94] of the consecutively acquired RF signals was 
applied on the acquired frames acquired at a frame rate of 1000 frames/s with a kernel size equal 
to 5 wavelengths of the imaging probe and 90% overlap to estimate incremental axial displacement 
as a result of oscillatory radiation force. Cross-correlation coefficient maps were also generated to 
determine the level of decorrelation noise, which is an indicator of the estimation accuracy. After 
low-pass filtering with a cutoff frequency at 100 Hz, the 50-Hz displacement was obtained, and a 
peak-to-peak displacement map could be generated across the axial direction.  A maximum peak-
to-peak displacement value was found across the axial direction. Based on the maximum peak-to-
Figure 3.1 Schematic of the 1D HMI setup. 
  26 
 
peak displacement value, we calculated -3 dB and -6 dB displacement focal zone over the axial 
direction.  The results allowed for monitoring of tissue displacement profile across targeting depth 
during both focal spot localization and HIFU ablation. The peak-to-peak displacement profiles 
were estimated across all imaging depths for all specimens and were plotted against imaging depth.  
In HMI, the acoustic radiation force can be described by [95], [96] F(t) = #]P(W)3                                                            (3.1) 
where 𝑐  is the speed of sound (1540 m/s in soft tissue), 𝐼(𝑡) (W/cm2) is the intensity and 𝛼 
(dB/cm/MHz) is the  absorption coefficient of the tissue. Assuming the homogeneity within the 
specimen, the change in the radiation force F was thus only dependent on the intensity	𝐼(𝑡). 
Subsequentially, higher HMI displacement 𝐷 is indicative of higher radiation force which induced 
vibration. Therefore, the amplitude of peak-to-peak HMI displacement is directly correlated with 
acoustic intensity in a homogenous phantom or tissue. Based on this relationship, the -3 dB and -
6 dB focal zones were computed based on the maximum peak-to-peak displacement amplitude in 
the same trial. In in vitro liver experiments, 2-min tissue ablation was performed to generate lesion 
in the targeted area. Lesion locations were compared with corresponding focal spot localization 
results. 
During ablation, the in situ acoustic intensity was equal to 4200 W/cm2 and the duration 
was equal to 120 s. Once a thermal lesion was generated, a post-ablative HMI was performed 
(𝐼𝑠𝑝𝑡𝑝 = 4200 W/cm2, duration = 1s) to obtain the stiffness contrast map. The midpoint of the 
lesion in histology was measured to represent the location of the lesions. The midpoint of the -3dB 
focal region was thus estimated to represent the focal spot localization method for comparison 
purposes.  
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3.2.3 HIFU focal spot localization in 2D 
A 93-element, PZT-4 ceramic focused transducer (individual element diameter = 10 mm, 
overall out diameter = 110 mm, inner diameter = 41 mm, and focal depth=70 mm. H-178, Sonic 
Concepts Inc., Bothell, WA, USA) was used for HIFU. The HIFU center opening is designed to 
always locate the imaging array confocally. All HIFU channels were synchronously excited by a 
25-Hz amplitude-modulated 4.5 MHz signal generated by a dual-channel waveform generator 
(33522A, Agilent Technologies Inc., Santa Clara, CA, USA). The -6dB focal region has an 
ellipsoid shape with 1.35 mm in the axial direction and 0.25 mm in the lateral direction. A 64-
element phased array transducer (P4-2, ATL., Bothell, WA USA) with a center frequency at 2.5 
MHz was confocally aligned with the HIFU transducer to transmit and receive through a 4-board 
VDAS system (V-1, Verasonics, Bothell, WA, USA) at a sampling frequency of 10 MHz (Figure 
3.2). 
 
In the 1D system, RF signals were directly acquired from the single-element transducer. 
While in the 2D system, graphical processing unit (GPU) was used to perform efficient 
beamforming [97]–[99]. The channel signals were acquired individually through the 64-channel 
Figure 3.2 Flowchart of the 2D HMI setup. 
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phased array probe through VDAS system using a custom flash plane wave transmits imaging 
sequence. A GPU-based algorithm was used to beamforming and upsampling the RF signal to 
80MHz. The lateral resolution is 0.5 mm in obtained 2D HMI images. The acquired element data 
to the RF signals. The frame rate of both systems was 1000 frames/s. 
To assess the capability of the method in the presence of aberration, an aberration layer 
[100], [101] was introduced between the HIFU transducer and the gel phantom. The aberration 
layer made of agar was placed above the gel phantom in order to create phase distortion within the 
incident HIFU beam. The incidence angle between the primary beam direction and the wedge-
shaped aberration layer is 11°.  
In order to assess the accuracy of the aforementioned focal spot localization method, it is 
idealistic to detect the apparent focal region by searching for the highest rate of temperature change 
as a comparison. Nevertheless, the thermocouple could not be used in this study in order to avoid 
imaging artifacts. Here, we propose an alternative approach to measure the apparent focal spot 
based on the relative change of monitoring displacement profiles during HIFU ablation across the 
imaging depth.  That is, the location with earliest decreasing of displacement decrease is identified 
as the focal spot where the temperature rose fastest. From our previous work [92],  the peak-to-
peak amplitude of the HMI focal displacement first increases then decreases as tissue undergoes 
initial softening followed by stiffening during slow thermal ablation, which is the pattern of 
stiffness change under slow denaturation (Figure 3.2(B)). Assuming that the targeted in vitro liver 
tissue is homogeneous and the target region coagulates at the same temperature, then the time point 
at which the tissue starts to stiffen can indirectly indicate that the tissue has reached the temperature 
causing irreversible protein denaturation [67], [102]. In order to successfully find the peak in this 
variation, an envelope detection algorithm was applied across the 2-min long monitoring 
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displacement to detect the time-point at which the tissue started to undergo stiffening.  The time 
to undergo stiffening was computed across all acquired depths. The depth with the shortest time 
to stiffening (TTS) was considered as the actual focal spot (AFS) since thermal dosage was 
delivered most at this depth.  
 
Figure 3.3 (A) Overview of the generation of oscillatory radiation force and an example of HMI 
peak-to-peak displacement recorded in vitro canine liver specimen. The -3dB and -6dB focal zone 
was computed based on the maximum peak-to-peak displacement amplitude. (B) HMI monitoring 
during 2-minute ablation at 3 depths (a), (b) and (c). The 3 depths are marked in (A).   	
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3.3 Results 
3.3.1 Experimental validation in 1D 
3.3.1.1 1D HMI on phantoms 
The intensity of the focused ultrasound beam was detectable by estimating the harmonic 
displacement in homogeneous gelatin phantoms. Figure 3.3(A) depicts an example of 1D peak-to-
peak displacement profile along the axial direction in a gelatin phantom. The targeted region could 
be represented as the -3dB focal zone. Figure 3.3(B) shows the representative 2-min HMI 
displacement of 3 depths (a), (b) and (c) within the focal region. The displacement at all three 
depths initially increased then decreased as tissue underwent initial softening followed by 
stiffening during slow thermal ablation. The time point at which the tissue started to stiffen is 
marked with a black line and arrow. The time taken to reach this time point was computed as the 
time to stiffening (TTS). 
 
3.3.1.2 1D HMI on in vitro liver specimens 
An example of HMI displacement image of an in vitro canine liver specimen using the 1D 
system before and after ablation is shown in Figure 3. The -3dB and -6dB focal zone was estimated 
based on the 1-s HMI before ablation. A post-ablative HMI was recorded after 2-min ablation 
monitoring. The peak-to-peak displacement contrast was capable of delineating the lesion 
generated when compared against gross pathology. The midpoint of the lesion in pathology on the 
right panel was measured to represent the location of the lesion.  
Linear regression was performed in nine thermal lesions in order to establish the 
relationship between the focal spot location identified with HMI and the shortest TTS location. 
The R2 value from the statistical regression analysis equals to 0.879 and p<0.0002. The slope of 
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the best-fit line is 0.930 ± 0.155 with a 95% confidence interval of 0.562 to 1.298.  Another linear 
regression was performed on those lesions between the location of focal regions from focal spot 
localization and the location of true physical lesions from histology. The R2 value from the 
statistical regression analysis is 0.638 and p<0.001 as shown in Figure 4. The slope of the best-fit 
line is 0.743 ± 0.212 with a 95% confidence interval of 0.242 to 1.243.   
 
 
Figure 3.4 1D HMI displacement image of an in vitro canine liver specimen before and after 
ablation. The -3dB and -6dB focal zone was estimated based on the maximum peak-to-peak 
displacement amplitude. A post-ablative HMI was recorded after 2-min ablation. The peak-to-
peak displacement contrast could indicate the lesion generated when comparing with the 
transverse section in gross pathology on (B). The red lines are indicating the corresponding -3dB 
and -6dB regions in gross pathology. 
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Figure 3.5 Verification of focal spot localization results. (A) Comparison between the midpoint of 
-3dB focal zone computed from focal spot localization with the location of the corresponding 
shortest TTS points. The R2 value from the statistical regression analysis is 0.879 for the 9 data 
points used in this study. The corresponding p value is <0.0002. (B) Comparison between the 
midpoint of -3 dB focal zone computed from focal spot localization with midpoint of lesion from 
gross pathology. The R2 value from the statistical regression analysis is 0.638 for the 9 data points 
used in this study. The corresponding p value is < 0.001.  
 
3.3.2 Experimental validation in 2D 
3.3.2.1 2D HMI on phantoms and in vitro liver specimens 
Figure 3.6(A)-(C) shows the estimated focal region using the HMI-based focal spot 
localization method overlaid onto the B-mode image of gelatin phantoms. The yellow region 
represents the -6dB focal region, and the red region represents the -3dB focal region. The 
transducer was moved across various lateral and axial locations within the phantom. In Figure 3.7, 
the aberration layer is delineated by the blue dash line. The red region represents the -3dB focal 
region without the aberration layer, and the blue region represents the -3dB focal region with the 
aberration layer. A shift of the focal spot due to aberration was detected. The axial movement of 
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the focal spot was within the range of 66.3 to 69.8 and 65.9 mm to 69.7 mm in phantom and liver 
respectively. Figure 3.8 shows the estimated focal region using the HMI focal spot in in vitro liver 
specimens. In Figure 3.9, linear regression was performed in eight lesions in order to establish the 
relationship between the location of focal regions from focal spot localization and the location of 
the corresponding shortest TTS points. The R2 value from the statistical regression analysis is 
0.869 and p < 0.001. The slope of the best-fit line is 1.079 ± 0.171 with a 95% confidence interval 
of 0.661 to 1.498.  Another linear regression was performed in those lesions between the location 
of the focal regions predicted by HMI and the true location of the lesions from histology. The 
R2 value is 0.821 at p < 0.002. The slope of the best-fit line is 1.415 ± 0.269 with a 95% confidence 
interval of 0.756 to 2.074. 
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Figure 3.6 Focal spot localization application on phantom in 2D HMI system. The focal region 
from focal spot localization method was overlaid to the B mode image in (A) (B) and (C): the 
yellow region represents the -6dB focal region, and the red region represents the -3dB focal region.  
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Figure 3.7 Focal spot localization application on in vitro liver in 2D HMI system. The focal region 
of the focal spot localization method was overlaid on the B mode image: the yellow region 
represents the -6dB focal region, and the red region represents the -3dB focal region. 
Figure 3.8 Focal spot localization application on phantom in 2D HMI system. The aberration layer 
is delineated with blue dash line. The red region represents the -3dB focal region without the 
aberration layer, and the blue region represents the -3dB focal region with the aberration layer. 





3.3.2.2 2D HMI on ex vivo human breast tumor specimens 
A representative application of the estimated focal region using the HMI focal spot in ex 
vivo human breast specimens is shown in Figure 3.10: (A) normal breast tissue and (B) IDC. The 
focal region of the focal spot localization method was overlaid on the B mode image: the yellow 
region represents the -6dB focal region, and the red region represents the -3dB focal region.  
Figure 3.9 Verification of focal spot localization results in 2D HMI system. (A) Comparison 
between the midpoint of -3dB focal zone computed from focal spot localization with the location 
of the corresponding shortest TTS points. The R2 value from the statistical regression analysis is 
0.869 for the 8 data points used in this study. The corresponding p value is < 0.001. (B) 
Comparison between the midpoint of -3dB focal zone computed from focal spot localization with 
midpoint of lesion from gross pathology. The R2 value from the statistical regression analysis is 
0.821for the 8 data points used in this study. The corresponding p value is < 0.002.  





Several ultrasound-based imaging modalities have been proposed for image guidance and 
monitoring of HIFU surgery. However, accurate localization and characterization of the effective 
region of treatment in real-time remain as the obstacles in the clinical implementation of HIFU 
ablation. In this study, we investigated on an important challenge for focused ultrasound treatment 
planning, i.e. the visualization of the focal region prior to treatment. In this study, a focal spot 
localization method was developed with a radiation-force-based technique of HMI based on both 
1D and 2D systems. The capability of HMI to simultaneously generate oscillatory radiation force 
and monitor the induced local displacement at the focus are considered unique advantages. 
Minimal interference between high power FUS and diagnostic beams is achieved by performing 
analog and digital filtering, thus phantom/tissue displacements can be accurately estimated using 
the filtered RF signals.  
Figure 3.10 Focal spot localization application on ex vivo human breast tissue in 2D HMI system: 
(A) normal breast tissue and (B) IDC. The focal region from focal spot localization method was 
overlaid on the B mode image: the yellow region represents the -6dB focal region, and the red 
region represents the -3dB focal region. 
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The method presented herein was also shown to be efficient requiring under 1s for data 
acquisition. Based on previous thermometry studies, a one second excitation under 25 Hz 
modulation frequency consisted of 50 oscillation cycles was used to reliably obtain steady-state 
HMI displacement while avoiding any significant temperature rise [78].  It is noteworthy that 
despite the speed of sound can vary with temperature, the offset caused by the speed of sound 
change could be filtered out as DC component from the oscillation in the focal spot localization 
process. 
The midpoint of the -3dB focal region was thus estimated to represent the focal spot. The 
midpoint of the -6dB focal region was also estimated but tend to be less accurate because the -6dB 
focal region is bigger than the -3dB on which could have introduced noise in the focal spot 
estimation. We have shown that the region with the highest heating rate is also the region with the 
shortest time to stiffening. This was in agreement with its predicted focal spot by HMI in Figure 
3.7(A). However, Figure 3.7(B) shows a slight discrepancy between our method and gross 
pathology in the evaluation of the location of the lesion in this study. The lesions measured by 
gross pathology tend to be closer to the transducer by an average difference of 2.59 mm than the 
locations estimated by HMI. The discrepancy can be due mainly to the heat diffusion of HIFU-
induced lesions. It is known that the geometry of the lesion axial cross section may not be ideal 
ellipsoidal shape but a tadpole lesion with centroids displaced from the focus toward the transducer 
[103]–[105]. It is likely that the discrepancy between the gross pathology location and the HMI 
location is due to the tadpole-shaped lesions that have grown towards the transducer. This is 
consistent with the linear regression results in Figure 3.5(B) where the axial midpoint of lesions 
tends to be closer to the tissue surface than the estimated focuses. A single expert was used for 
manual segmentation of the lesion. The manually segmented lesion on the pathology may have 
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also introduced discrepancies. In 2D HMI, the axial and lateral resolutions were 0.087 mm and 0.3 
mm respectively. In lesion measurement, although the boundaries of the lesions have sharp 
contrast from the surrounding normal tissue, the physical measurement was on 0.1 mm scale. 
Despite our successful implementation on both 1D and 2D HMI platforms, there are several 
limitations.  One limitation of this study is the absence of temperature measurement during HIFU 
treatment. The placement of a thermocouple within the tumor typically generates additional heat 
accumulation due to the beam interference with the thermocouple. This would influence the 
associated displacement estimation. Hence, simultaneous temperature measurement was excluded 
in this study. However, a location with shortest TTS, which may suggest quickest coagulation, was 
considered as the focal spot in the axial direction.  Furthermore, although off-line processing was 
used in this study, the 2D HMI system has the fundamental capability of on-line monitoring.  
 
3.5 Conclusions and Summary 
A new HIFU treatment planning method was described that used oscillatory radiation force 
induced displacement amplitude variations to detect the HIFU focal spot before lesioning. This 
method was applied on tissue-mimicking phantoms and in vitro tissues with both the 1D and 2D 
HMI systems. Using this method, we were able to visualize the HMIgFUS focal region at variable 
depths. By comparing the estimated displacement profiles with AFS point and with lesion 
locations in pathology, we demonstrated the feasibility of using this HMI-based technique to 
localize the HIFU focal spot and predict lesion location during the planning phase. The same 
application feasibilities were also demonstrated in a 2D preclinical system. We concluded that 
HMI has the potential of providing the capability for HIFU planning.  
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 CHAPTER 4. Real-time lesion quantification in Harmonic 
Motion Imaging guided Focused Ultrasound (HMIgFUS) 
4.1 Introduction 
There are several techniques currently being investigated to detect real-time treatment 
performance of HIFU. Magnetic resonance imaging (MRI) thermometry [106], [107] is used to 
detect temperature rise across the treatment area. However, MRI guidance can be expensive and 
time consuming compared to ultrasound-based HIFU guidance; the temporal resolution for this 
clinical applications is usually between 2 and 6 s [36]. Among the ultrasound guidance techniques, 
conventional B-mode-based ‘hyperecho’ tracking is not robust for HIFU monitoring as it is 
sensitive to air bubbles, which occur at high temperatures and usually lead to over-treatment of the 
targeted region [108], [109]. Passive acoustic mapping (PAM) has also been investigated regarding 
it capability of monitoring HIFU ablation by reconstructing the emissions generated by inertially 
cavitating bubbles during HIFU. However, the estimates of cavitation location and intensity are 
also prone to errors due to the limited axial resolution [110], [111]. 
Over the past two decades, ultrasound elasticity imaging has expanded from diagnostic  
technique to include therapy guidance and monitoring based on tissue stiffness change [71], [73], 
[112]. Compared to bubble- or cavitation-based methods, elasticity imaging does not rely on, or is 
affected by, boiling air bubbles formed at the focus but monitors the change in the tissue 
characteristics. However, most elasticity imaging techniques require HIFU to be interrupted for 
reliable monitoring, and therefore cannot detect the onset of lesion formation in real time, 
significantly increasing the treatment duration and cumulatively reduces the efficiency of a HIFU 
treatment. 
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Harmonic Motion Imaging (HMI) is a radiation-force-based ultrasound elasticity imaging 
technique which is designed for both tissue relative stiffness imaging and reliable HIFU treatment 
monitoring. An amplitude-modulated (AM) HIFU beam is transmitted through a focused 
ultrasound (FUS) transducer to induce tissue vibration at the focal region. The oscillatory response 
from the tissue can be tracked using radio-frequency (RF) signals acquired with a confocally-
aligned imaging transducer [49], [92]. The oscillatory displacement amplitude, namely HMI 
displacement, is monitored continuously to provide real-time tissue stiffness change during the 
treatment. Without interrupting the ablative procedure, Harmonic Motion Imaging guided Focused 
Ultrasound (HMIgFUS) can be applied with optimal efficiency to the targeted area. Several studies 
have been published showing feasibility of HMI in  post-surgical human breast tissue [113], ex 
vivo canine liver [78], [114] and in vivo mice [80], [81].  A fast imaging and processing algorithm 
is essential to ensure real-time lesion mapping. Recently, HMI was shown capable of streaming 
HMI displacement in real time at 15 frames per second [115]. Although the oscillatory HMI 
displacement contains important information on tissue stiffness change, it does not provide 
information on the lesion location or lesion size itself in real time. A fast lesion mapping method 
that can inform physicians intuitively on the progression of thermal lesioning in real time without 
sacrificing the frame rate is thus wanted.  
Our objective in this chapter is first to develop a HMIgFUS-based lesion quantification 
method to map and quantify HIFU-induced thermal lesions. We also aimed at demonstrating the 
accuracy as well as reproducibility of the lesion quantification method through gross pathology 
validation in vitro and in vivo. Finally, we aimed at implementing a fast lesion mapping method 
for online processing to achieve lesion formation monitoring during HMIgFUS treatment in real 
time. 
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4.2 Methods 
4.2.1 Development of lesion quantification method 
In HMI, the oscillatory displacement is monitored continuously through a phased array 
imaging transducer. The changes in estimated displacement amplitude can be used to indicate the 
relative stiffness change when the lesion is starting to form at the focal region. 
Figure 4.1 shows an illustration of the experiment setup. The HMIgFUS system consisted 
of a FUS transducer and a phased array imaging probe confocally-aligned through the central 
opening (diameter = 41 mm) of the FUS transducer. The FUS transducer was a 93-element phased 
array (𝑓3= 4.5 MHz, and D = 70 mm, Sonic Concepts Inc., Bothell WA, USA). The imaging probe 
was a 64-element phased array (𝑓3  = 2.5 MHz, P4-2, ATL/Philips, Bothell, WA, USA). A dual-
channel arbitrary waveform generator (AT33522A, Agilent Technologies Inc. Santa Clara, CA, 
USA) was used to generate an AM sinusoidal signal to drive the FUS transducer through a 50-dB 
power amplifier (325LA, E&I, Rochester, NY, USA). The imaging probe was inserted through the 
central opening and confocally aligned with the FUS transducer. The imaging probe was 
transmitting and receive through an ultrasound imaging research system (Vantage, Verasonics, 
Bothell, WA, USA) with a pulse repetition frequency (PRF) at 1000 Hz. The FUS total output 
acoustic power was within the range of 6.4 - 8.6 W from radiation force balance measurements 
[116].  A T-type bare wire thermocouple with a diameter of 80 µm (Physitemp Instruments Inc., 
Clifton, NJ, USA) was inserted into the tissue and aligned with the focal spot for temperature 
monitoring at the focal region.  





During real-time HMIgFUS, the RF channel data was acquired at a PRF of 1000 frames/s. 
In order to calculate the peak-to-peak HMI displacement without sacrificing the display frame rate, 
only 10 consecutive frames within a single HMI vibration were obtained at each acquisition and 
transferred to a host computer. The RF channel data matrix was placed into a GPU matrix within 
Matlab and multiplied by a beamforming sparse matrix to get the beamformed RF data [99], [115]. 
A 1D cross-correlation method [94] was  used to estimate the incremental axial displacement 
between 2 consecutive RF frames. HMI peak-to-peak displacement maps were calculated over 
each of the 10 frames of HMI displacement maps by subtracting the minimum displacement from 
the maximum displacement on each pixel. When the processing is finished, another 10 frames will 
be acquired for processing. The peak-to-peak HMI displacement map averaged over the first 1s of 
treatment served as a reference map.  The HMI lesion map was generated by subtracting the 
Figure 4.1 HMIgFUS experimental setup and transducers. 
  44 
 
reference HMI image from the current HMI peak-to-peak displacement map (Figure 4.2) to be 
displayed on computer screen (Figure 4.3).  
  
 
Six in vitro canine liver specimens were used for this study as they are relatively 
homogeneous, allowing easy optical delineation of the lesions in gross pathology. Liver specimens 
were prepared and degassed for 2 hours before each experiment. After ablation, each liver 
specimen was carefully sectioned at the imaging plane under the guidance of B-mode for gross 
pathology. The lesion area was delineated based on the color change in tissue. The depth, width 
and area of the lesions measured on gross pathology were compared with HMI lesion mapping. 
We tested 0 dB, -1.5 dB, -3 dB and -6 dB thresholding. We then chose to set a -3 dB or 30% 
displacement decrease as the threshold to discriminate the ablated from unablated tissue as it yields 
the best correlation with gross pathology. The largest region closest to the geometric focus was 
identified as the lesion.  
 
 
Figure 4.2 Schematic of HMI lesion map generation. 




4.2.2 In vivo implementation of lesion quantification 
The animal experiment protocol was approved by the Institutional Animal Care and Use 
Committee (IACUC) of the Columbia University. The transgenic mouse model (K-
rasLSL.G12D/+; p53R172H/+; PdxCre (KPC)) [117], [118] was used to develop pancreatic tumor 
which is pathophysiologically resembling human pancreatic ductal adenocarcinoma (PDA). One 
KPC mouse was used for this study. The mouse was laying supine under isoflurane anesthesia 
with it abdomen shaved and covered with ultrasound gel, with a degassed water tank on top to be 
coupled for ultrasound imaging. To precisely locate the pancreas, an 18.5-MHz diagnostic probe 
Figure 4.3 Flowchart of real-time HMI reconstruction algorithm. 
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(L22-14v, Verasonics, Bothell, WA, USA) was used in the planning stage providing high 
resolution B-mode images to locate and differentiate organs. By aligning the HMI imaging plane 
with the high-resolution B-mode images, the HMI images are spatially registered with the B-mode 
images. In the treatment monitoring stage, the center imaging probe of HMIgFUS was replaced 
with a 104-element phased array (𝑓3  = 7.8 MHz, P12-5, ATL/Philips, Bothell, WA, USA) for 
higher resolution more adapted to small animals. The treatment power on the tumor was 6.4 W 
with 60 s duration.   
The mouse was immediately sacrificed after the previously described procedure. Because 
gross pathology was incapable of distinguishing the ablated lesion from the pancreatic tumor, the 
whole pancreas along with the tumor was harvested for histological evaluation. The excised tissue 
was first fixed in 4% paraformaldehyde. After post-fixation processing, tissue was embedded in 
paraffin, sectioned, and stained with hematoxylin and eosin (H&E). Bright field microscopy 
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4.3 Results 
4.3.1 Real-time HMIgFUS ablation monitoring 
 
 
The fast lesion mapping of HMIgFUS can stream the HMI displacement, HMI 
displacement overlaid on B-mode and HMI lesion map to the computer screen (Figure 4.4) at an 
average frame rate of 2.4 Hz. In the HMI displacement map, positive displacement is towards the 
transducer and negative displacement is away from the transducer 
Figure 4.4 Real-time HMI displacements. A computer screenshot is shown with the left panel 
showing real-time HMI displacements. The middle panel shows the filtered HMI displacements 
overlaid on the B-mode image. A HMI lesion map (right) is shown in the right panel with blue 
denoting lesion. Corresponding HMI lesion area after -3 dB thresholding is shown on the right 
side. 
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4.3.2 In vitro experimental validation  
In order to prove the reproducibility of the technique, we have generated 13 lesions with 
HMIgFUS using different acoustic powers (6.4 W and 8.6 W) with different treatment durations 
varying from 90s to 120s. The lesions were detected and visualized at 2.4 Hz.  
Figure 4.5 shows a representative case of HMIgFUS lesion monitoring over 90s ablation. 
Yellow indicates HMI peak-to-peak displacement amplitude increase (softening) and blue 
indicates HMI peak-to-peak displacement amplitude decrease (stiffening). No lesioning was found 
by HMI until 50s into the treatment when a dark blue spot was detected at the focal spot region 
(Figure 4.5(a)) indicating tissue stiffening. The lesion was found to grow during ablation, which 
is also quantified in Figure 4.5(d) showing that the lesion size increased after 50s. When 
temperature rises above a certain threshold, liver tissue undergoes irreversible stiffening change, 
which is caused by protein denaturation. According to established studies [58], [119], [120], 58–
60°C is the conventional “threshold” for the formation of HIFU lesions in the liver. The temporal 
temperature profile (Figure 4.5(e)) was obtained showing the temperature at the focal spot reaching 
the threshold of 60°C at 30s (denoted with red line). Normalized HMI displacement within the 
focal region (Chapter 3) was plotted against the temperature clearly showing the displacement 
change with temperature increase. A gross pathological cross section of the lesion was shown in 
Figure 4.5(b) for comparison with the final HMI lesion map Figure 4.5(c).  




Figure 4.6 is another representative case of 120s HMIgFUS lesion monitoring.  Lesioning 
was detected by HMI after 40s of sonication with a decrease in displacement at the focal spot 
indicating tissue stiffening (Figure 4.6(a)). Lesion growth during ablation is also quantified in 
Figure 4.6(d) showing that the lesion size increased after 50s. The temperature profile over time 
Figure 4.5 Example case of HMIgFUS lesion monitoring on 90s ablation. Lesion developing 
overtime is shown in (a) with blue indicating the formation of the lesion. Gross pathology of the 
lesion (b) is shown along with the HMI lesion map at the end of ablation (c). (d) HMI lesion size 
development overtime. (e) Temperature measurement from thermocouple. (f) HMI displacement 
change during the ablation. 
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(Figure 4.6(e)) showed that the temperature at the focal spot reached the 60°C threshold at 30s 
(denoted with red line). Normalized HMI displacement within the focal region was also plotted 
against temperature clearly showing the displacement change with temperature. A gross 
pathological cross-section of the lesion was shown in Figure 4.6(b) in comparison with the HMI 
final lesion map Figure 4.6(c).  
 
 
Figure 4.6 Example case of HMIgFUS lesion monitoring on 120s ablation. Lesion developing 
overtime is shown in (a) with blue indicating the formation of the lesion. Gross pathology of the 
lesion (b) is shown along with the HMI lesion map at the end of ablation (c). (d) HMI lesion size 
development overtime. (e) Temperature measurement from thermocouple. (f) HMI displacement 
change during the ablation. 
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Statistical analysis was performed with linear regression in 13 HMIgFUS-induced lesions 
to compare the lesion dimension identified with HMI and gross pathology. The R2 value from the 
linear regression analysis equal to 0.81 and 0.85 in depth and width. The linear regression 
performed in the lesion area gives a R2 equals to 0.75 (Figure 4.7).   
 
In HIFU clinical applications, multiple-lesion ablations are often needed to treat the entire 
target region. When a few lesions come close together, the lesions generated later start to merge 
into those created before.  An example of a three-lesion HMIgFUS case was shown in Figure 4.8. 
The three lesions are 3 mm apart at the same ablation power and duration starting from location 1 
and then moving towards the right to locations 2 and 3 (Figure 4.8(a)). Same lesion quantification 
protocol was used in each location. After combining lesion maps from 3 locations, a final 
combined HMI lesion map was obtained in Figure 4.8(d).  
Figure 4.7 Lesion dimension comparison between gross pathology and HMI lesion map in depth 
(left), width (middle) and area (right). 




Figure 4.8 Multiple-lesion map using HMI in comparison with gross pathology. (a) HMI lesion 
map at lesion 1, 2 and 3. (b) Lesion gross pathology. (c) HMI lesion map at the end of ablation at 
lesion 1, 2 and 3. (d) Combined HMI lesion map. 
 
4.3.3 In vivo experimental validation  
HMIgFUS lesion maps within the tumor area at the beginning (t = 3s) and the end (t = 59s) 
of the ablation are shown in Figure 4. (a-b). The pancreatic tumor was delineated based on the 
high-resolution B-mode images. In Figure 4.9(a), the lesion map within the tumor was 
homogeneous and no lesion was indicated at the onset of ablation. Figure 4.9(b) exhibits stiffening 
within the tumor after a 59s-ablation with a displacement reduction rate of 43.3%, suggesting 
lesion formation. The H&E staining results in Figure 4.9(c) confirmed that the thermal lesion was 
generated in the tumor with apparent hemorrhage and tissue disruption. 





In the field of MRI and ultrasound imaging, numerous guidance techniques have been 
developed for the 3 stages of HIFU treatment: planning, monitoring and assessment.  Although 
numerous methods have been developed to assist the 3 stages of HIFU treatment, real-time HIFU 
monitoring still remain as a challenge. Real-time HIFU monitoring, especially lesion mapping, is 
Figure 4.9 HMIgFUS lesion formation monitoring in mouse pancreatic tumor. HMIgFUS lesion 
map at (a) the beginning (t = 3 s) and (b) the end (t = 59 s) of ablation with tumor and adjacent 
organs marked. (c) H&E stained image of the pancreatic tumor after HIFU ablation show tissue 
disruption (red arrow), hemorrhaging (yellow arrow) and cell death (blue arrow). The scale bar 
represents 1 mm. 
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essential during HIFU procedure as it can help avoid any over- or under-treatment. HMIgFUS is 
capable of performing HIFU monitoring based on the stiffness change of the tissue without 
interrupting treatment. Throughout this study, we developed a lesion quantification method using 
HMIgFUS, and investigated the feasibility of real-time lesion formation monitoring, which 
incorporated a GPU-based, fast beamforming method. The lesion quantification method was 
validated through in vitro experiments in liver and showed promising results in vivo.  
In addition to lesion stiffening, softening was also detected at the focal spot when 
temperature is within the range of 40-60°C before the lesion started to form (Figure 4.5(a) at 30s).  
This agreed with previous literature on liver showing a slow,  reversible shear modulus decrease 
under HIFU treatment before reaching the threshold of irreversible protein denaturation [67].  At 
the end of treatment, softening is also detected around the lesion boundary area in most cases 
indicating heat diffusion to adjacent region.  We found that heat diffusion after HIFU is turned off 
will not affect the lesion size significantly by comparing it with another lesion map acquired 5 min 
after ablation. According to the temperature profile obtained by the thermocouple, temperature 
measured from the focal spot drops back to room temperature rapidly within 1 min after HIFU is 
turned off. A post-treatment HMI was performed 5 min after HIFU exposure showing the lesion 
dimensions remain the same. Therefore, the lesion map at the end of HMIgFUS can represent the 
final lesion.  Since the speed of sound change is filtered out from the displacement map [92], the 
effect of speed of sound change due to temperature increase can also be excluded. Furthermore, 
the increase in attenuation can occur during thermal lesioning [87], resulting in increased 
absorption therefore increased radiation force within the stiffer lesioning area. However, it has 
been shown that the decrease in displacement amplitude occurs approximately after reaching 60°C 
due to the combined effect of viscoelasticity changes and lesion growth overpowering the effect 
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of attenuation [77], [121]. The increased radiation force during ablation may generate an opposite 
lesion-to-background contrast by generating higher HMI displacement inside the lesion, which 
was not observed in this study. It is therefore concluded that the stiffening process is dominant 
over the change of absorption coefficient in HIFU ablation in liver.  
Despite our successful implementation on real-time HMIgFUS platforms, one limitation 
was that there was no absolute threshold of relative stiffness change to distinguish ablated liver 
tissue. However, the displacement change during and after treatment has shown enough contrast 
to delineate the HIFU lesion. -3 dB or 30% decrease out of 0 dB, -1.5 dB and -6 dB showed the 
best agreement with the gross pathology. This can be improved by optimization study, which can 
adapt the lesion threshold for each specific specimen. The lesion size was not quantifiable on H&E 
staining for 2 reasons: 1) it was difficult to register the imaging plane with the cutting plane in 
histology due to the harvest process; 2) soft tissue shrinks in the paraformaldehyde fixing process, 
which makes the lesion size smaller when compare with the actual lesion size in vivo. A 
registration method will be used in the future to register the orientation of the lesion with the help 
of surrounding organs. Another limitation of this study lies in the fact that only slow denaturation 
induced ablation was included in the study. However, previous work [77] from our group has 
shown that HMIgFUS is robust under faster treatments such as boiling in monitoring the lesion 
formation in the presence of strong cavitation events with good displacement contrast across the 
entire treatment window. The present study may have the potential to be applied on cavitation 
induced HIFU treatment in the future. 
As a final point, HMIgFUS combines HIFU and real-time elasticity imaging on the same 
device with the advantage of lesion formation monitoring without interfering HIFU treatment.  
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Future studies will consider the correlation between tissue structures and HMI characteristics to 
better understand tissue mechanical responses during HMIgFUS ablation.  
 
4.5 Conclusions and Summary 
A real-time (2.4 Hz) lesion detection and ablation monitoring method was developed using 
oscillatory radiation force induced displacement amplitude variations in real time. Lesion size 
monitoring was achieved in canine liver in vitro and initial in vivo feasibility was shown in a mouse 
pancreatic tumor model. Using this method, the HMIgFUS focal region and lesion formation were 
visualized in real time at a feedback rate of 2.4 Hz. By comparing the estimated lesion size against 
gross pathology, we have shown the feasibility of using HMIgFUS to monitor treatment and lesion 
formation without interruption. The study presented herein validated that HMIgFUS could map 
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 CHAPTER 5． Focused ultrasound steering for Harmonic 
Motion Imaging (HMI) 
5.1 Introduction 
Over the past two decades, several radiation-force-based elasticity imaging techniques 
have been developed to estimate tissue stiffness and thus detect tumors using various forms of 
tissue perturbation for the detection of stiffer masses, including acoustic radiation force 
impulse(ARFI) imaging[122], vibro-acoustography[123] and shear wave elasticity imaging[124]. 
Harmonic Motion Imaging (HMI) is capable of monitoring the displacement in seamless 
synchronization with the application of radiation force, with applications to monitoring thermal 
ablation and tissue viscoelasticity evaluation [113], [121], [125]. 
Electronic steering is achieved by varying the delay of the sinusoidal signal applied to each 
element of the transducer to move the focal spot position from the geometric focal spot. The main 
interest of the electronic steering compared to the mechanical movement arises from the 
dramatically shorter time required to move the focal spot. The response time for electronic steering 
is approximately equal to the time-of-flight of the ultrasonic beam from the transducer to the focus 
(less or equal to 100 µs). Studies have indicated that using electronic steering can greatly increase 
the rate of tissue coagulation and reduce the total treatment time [126]. Using electronic steering 
can also help avoid poor coupling between transducer/skin interfaces introduced by mechanical 
movement. The main limitation of the electronic steering approach lies in the spatial steering range, 
typically on the order of 1 cm along a given direction [127], [128].  
In this chapter, electronic steering is proposed for facilitating HMI by electronically 
steering the focal spot to several different predetermined locations. This method offers the 
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advantages of significantly increasing the imaging area and shortening the imaging duration 
without physical movement of the transducer. 
 
5.2 Methods 
HMI measures the oscillatory response of the targeted region to an oscillatory radiation 
force. The radiation force is caused by applying amplitude modulation (AM) on the acoustic wave 
as it propagates through a medium. When an AM waveform is used to drive the focused ultrasound 
(FUS) transducer, the radiation force is oscillating at the modulation frequency 𝜔f, which is 25 
Hz in this study. 
 
In HMI, an oscillatory response is induced at the FUS focal zone due to the AM-FUS 
excitation, i.e., the HMI displacement [49], [55], [114]. Imaging was performed in a plane wave 
flash mode with a frame rate of 1000 Hz. The incremental axial tissue displacements were 
estimated by performing a fast 1D normalized cross-correlation [94] between sequentially acquired 
tracking lines.  
Geometric  
Focus d = 70 mm 
d 
Figure 5.1 HMI phased array transducers and schematic of steering. 
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The HMI system consisted of a FUS phased array and an imaging phased array confocally-
alignedthrough the central opening (diameter = 41 mm) of the HIFU transducer. The FUS 
transducer had 93 elements (𝑓3= 4.5 MHz, and D = 70 mm, Sonic Concepts Inc., Bothell WA, 
USA). The -3 dB focal size was equal to 0.3 mm (transverse) by 1.1 mm (axial) in water. The 
imaging probe had 64 elements (𝑓3  = 2.5 MHz, P4-2, ATL/Philips, Bothell, WA, USA). The FUS 
phased array operated through a four-board ultrasound system (V-1, Verasonics, Bothell, WA, 
USA) and the diagnostic probe is operated through another ultrasound imaging research system 
(Vantage 256, Verasonics, Bothell, WA, USA). A Fiber Optic Hydrophone (HFO-690, Onda, 
Sunnyvale, CA, USA) was used to measure the pressure field and assess steering range in water. 
HMI using a steered FUS beam was acquired in tissue-mimicking phantoms. Gelatin powder 
(Gelatin 50 bloom, MP Biomedicals, Irvine, CA, USA) was used to construct 3 homogeneous 
tissue-mimicking phantoms with elastic modulus of 10 kPa. The concentration of gelatin powder 
was 50.7 g L−1 yielding a stiffness of 10 kPa [93]. 
Using the Verasonics V-1 four-board ultrasound system with external power supply, the 
longest single transmit burst is 31 x 64 half-cycles, or 992 cycles.  To get longer burst for 
continuous wave transmission for HMI, several transmit-only events were put together in sequence 
in the script, with no other sequence control commands in between them.  Therefore, the system 
could start the next event as fast as it can after completing the prior transmit-only event, resulting 
in an idle time of roughly 10 microseconds between the transmit bursts. 
Assembling several transmit events in rapid sequence was also necessary to accomplish 
the amplitude modulation. Because the transmit power supply to the system’s square wave 
transmitters was fixed at a DC level, there is no mechanism for changing that supply voltage 
rapidly to provide amplitude modulation.  Therefore, the amplitude control of each transmit output 
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at the fundamental frequency was implemented by varying the pulse width of the transmit 
waveform using the “B” value in the parametric waveform definition on V-1.  So to produce 
an overall amplitude-modulated transmit output, a number of transmit-only events were put 
together each using a different “B” parameter value. 
The “B” parameter varied from a maximum of 100% down to a minimum of two (the 
shortest pulse the V1 transmit hardware can produce).  The amplitude of the fundamental term in 
the Fourier series for a square wave with relative pulse width PW is given by  
                                     Amplitude = sin p𝑃𝑊	 ×	t#u ×	tQ                                            (5.1) 
where PW was represented by parameter “B” when setting up each transmission.  
Another constraint of the V-1 system hardware design is that it cannot drive the transmit 
devices continuously at transmit frequencies above 2 MHz. With the 4.5 MHz FUS transducer, it 
constraint the transmit sequence to be ‘chopped’ into a series of active 4.5 MHz transmit pulses 
interleaved with idle intervals long enough that the average cycle rate over the entire interval 
remains below 2 MHz as shown in Figure 5.2. 





A pressure profile with steering was acquired in free field to calculate the focal pressure 
loss due to beam steering. A safe steering range was assumed when the highest grating lobe 
amplitude was under -6 dB.  Figure 5.3 shows the FUS pressure field in water with lateral steering 
at 0 mm, 0.85 mm, 1.7 mm and 2.55 mm. The grating lobe amplitude keeps increasing with the 
steering distance and exceeds -6 dB of the maximum pressure when the steering distance is over 
1.7 mm in lateral direction. 
Discrete AM 
Continuous AM 
*Duty cycle: 45% 
Figure 5.2 Comparison of continuous AM transmission waveform using function generator and 
discrete AM transmission wave form using Verasonics V-1 system with a duty cycle of 45 %. 
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The HMI displacement was imaged within the steering range of +/-1.7 mm and +/-2 mm 
in the lateral and axial direction in tissue-mimicking phantoms, respectively. A peak-to-peak 
displacement map was generated, and a maximum peak-to-peak displacement amplitude value was 
found. The maximum peak-to-peak displacement location was also found and plotted in Figure 
5.4(B) and Figure 5.4(C). Figure 5.4(B) shows that the maximum peak-to-peak displacement spot 
moves laterally from the geometric focus when lateral steering is applied (n = 5). Figure 5.4(C) 
shows that the maximum peak-to-peak displacement spot moves away in axial direction from the 
geometric focus when axial steering is applied (n = 5). 
Figure 5.3 Hydrophone measured peak positive pressure profile with corresponding intended 
steering distance in free field. 
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Figure 5.4 (A) Example of HMI peak-to-peak displacement map from a tissue-mimicking gelatin 
phantom. (B) In tissue-mimicking gelatin phantom, lateral location of maximum displacement 
point with corresponding lateral intended steering distance (n = 5). (C) In tissue-mimicking gelatin 
phantom, axial location of maximum displacement point with corresponding axial intended 
steering distance (n = 5). 
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Using the maximum peak-to-peak displacement amplitude value, we calculated -6 dB 
displacement focal zone to represent the radiation force engaged area. The peak-to-peak HMI 
displacement amplitude is directly correlated with acoustic intensity in a homogenous phantom or 
tissue [114]. Based on this relationship, the areas of the -6 dB displacement focal zone were 
computed based on the maximum displacement amplitude. In Figure 5.5, the ellipses indicating 
the theoretical targeted area were overlaid onto the focal area defined by -6 dB displacement focal 
zone. In Figure 5.5(a), the white area indicated the -6 dB displacement focal zone, which is also 
the radiation- force engaged region in the phantom. The focal zone has been found to be larger 
than the FUS spot in water due to the connectivity in the material. Regarding the shape of the focal 
zone, perfect ellipse is rarely seen in experiments as a result of the inhomogeneity in the phantom. 
With +/-1.7 mm lateral and +/-2 mm axial steering, the 5 raster steering sequences generated a 
total -6 dB excited region equaling 46.0 mm2, which is 2.3 times larger than the original -6 dB 
excited region of 19.9 mm2. Using the maximum speed of the positioner at 10mm/s, it takes 200ms 
to move the focal spot to the next axial location in Figure 5.5 (b). In order to raster scan the entire 
excited region in Figure 5.5(b), the transducer requires to be moved at least 15 times which total 
3s of mechanical movement plus the communication time between the PC and the positioner. In 
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Figure 5.5 Representative image of -6 dB excited region without steering (a) and with 2D 
steering (b). The ellipses indicating the theoretical targeted area were overlaid onto the focal area 
defined by -6 dB displacement excited region. 
 
5.4 Discussion 
Using the steered FUS beam, HMI can be used to image a 2.3 times larger ROI without 
requiring physical movement of the transducer. Using steering for HMI can be used to shorten the 
total imaging duration without requiring physical movement of the transducer. The main limitation 
of this study lies in the design of the FUS transducer, which constrained the effective steering 
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 CHAPTER 6. Harmonic Motion Imaging guided Focused 
Ultrasound (HMIgFUS) based human breast tumor 
characterization and treatment monitoring ex vivo  
6.1 Introduction 
Breast cancer is the most common cancer and the second leading cause of cancer death 
among women. In 2013, approximately 300,000 women were diagnosed with breast cancer and 
almost 40,000 died from the disease in the US [129]. Image-guided minimally-invasive treatment 
of localized breast tumor has become a subject of intensive research and several studies have 
assessed the feasibility of minimally-invasive breast tumor ablation techniques, such as 
radiofrequency ablation (RFA), cryoablation and high intensity focused ultrasound (HIFU) 
ablation [20]. Minimally-invasive treatment applies extreme temperatures, either high or low, to 
induce irreversible cell injury, tumor apoptosis and coagulative necrosis [21]. Compared with 
conventional surgical procedures the main advantages of minimally-invasive ablation lie in the 
fact that they are less invasive, less scarring and less painful, allowing for shorter recovery time 
[22].  
HIFU is an entirely non-invasive technique which focuses the ultrasound beam onto a small 
target volume to reach high focal power, resulting in temperature elevations causing coagulative 
necrosis in the target while surrounding structures are spared. Since the ultrasound wave penetrates 
through soft tissue without any surgical incision nor needle insertion, there are no damages to the 
skin or underlying tissues. Acoustic energy can induce temperature elevations at the focal spot in 
a few seconds and simultaneously induce cellular death and vascular destruction in normal and 
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tumor tissues [37]. Because of the steep thermal gradients involved, the boundaries of the 
ultrasound-treated volumes can be closely spaced until the entire target is covered.  
Clinically, fibroadenoma (FA) is the most common benign breast mass and may be 
accompanied by pain [130]. FA does not require treatment; however, palpable FA may cause 
distress in some patients, who then request removal. Compared with conventional surgical excision 
or other minimally invasive techniques, HIFU is completely non-invasive which provides better 
cosmetic results and shorter recovery time. Recently, a multicenter study using HIFU as an 
outpatient procedure treated 42 women with 51 FA [131]. They demonstrated that HIFU is 
effective in reducing the volume and other clinical symptoms of FA. HIFU has also been studied 
to ablate early stage malignant breast tumors in elderly patients who are not surgical candidates 
[38]–[40]. 
Currently, MRI and sonography are being used for guidance and monitoring of HIFU 
therapy. Both MR-guided HIFU (MRgFUS)[59], [132] and ultrasound-guided HIFU (USgFUS) 
methods have their advantages and disadvantages. MRI has the advantage of providing 
temperature data within seconds after HIFU exposure. However, MRI guidance is expensive and 
lengthy. Ultrasonic guidance provides the benefit of imaging using the same form of energy that 
is being used for therapy. Therefore, if the target can be well visualized with sonography, then the 
HIFU therapy may avoid potentially causing thermal injury to normal tissue. Worldwide, 
thousands of patients with uterine fibroids, liver cancer, breast cancer, pancreatic cancer, bone 
tumors, and renal cancer have been treated by USgFUS [30], [133], [134].  
Ultrasound elasticity imaging is used in addition to traditional B-mode ultrasound as a tool 
for differential diagnosis between normal and tumor in human breast based on tissue stiffness. 
Qualitative and quantitative tissue strain analyses using acoustic radiation force impulse imaging 
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(ARFI) technology has been developed for the diagnosis of breast masses [4], [10], [11]. The 
response of tissue to the acoustic radiation force is tracked as tissue displacement, which has been 
found to be correlated with local stiffness of the tissue. Vibro-acoustic tissue mammography is 
also a radiation force-based method, uses focused ultrasound to vibrate tissue at frequency (kHz) 
and utilizes the resulting response to produce images that are related to the hardness of the tissue 
[12], [13]. Supersonic shear imaging (SSI) utilizes a very fast (5000 frames/s) acquisition sequence 
to capture the propagation of shear waves [14] that provide information of the local viscoelastic 
properties [15], [16].  
Over the past decade, ultrasound elasticity imaging was not limited to the area of disease 
diagnosis but also emerged in the application of therapy guidance and monitoring [135], [136]. 
Harmonic Motion Imaging (HMI) is an all-ultrasound-based elasticity imaging technique designed 
for both reliable diagnosis and HIFU treatment monitoring. It utilizes a HIFU transducer to emit 
an amplitude-modulated (AM) beam for both thermal therapy while inducing a stable oscillatory 
tissue displacement at its focal zone. The oscillatory response, namely HMI displacement, is 
estimated using the radio-frequency (RF) signals recorded during the HIFU treatment through a 
confocally-aligned imaging transducer [49], [92]. The localized tissue response is monitored 
continuously from the onset of HIFU treatment and aims at providing clinicians the change in local 
tissue stiffness in order to prevent any under- or over-treatment. Since the HMI does not interrupt 
HIFU ablation, HIFU sonication was operated with a duty cycle of 100%. Several studies have 
been published as feasibilities ex vivo [78], [114], and in vivo [79], [80] using 1D [54] and 2D [99] 
systems. The overall goal of this study is to develop and test HMI system for real-time imaging 
and ablation monitoring in post-surgical breast specimens. 
 
  69 
 
6.2 Methods 
6.2.1 Post-surgical breast specimen collection 
Collection and handling of post-surgical breast specimens were approved by the 
Institutional Review Board (IRB) board of Columbia University and informed consent was 
obtained from all enrolled patients. Thirty-six small tissue specimens from mastectomy were 
obtained from 24 patients who underwent lumpectomy or mastectomy including 19 normal, 15 
invasive ductal carcinoma (IDC) and 2 fibroadenoma (FA). The age range of patients was 21-89 
years (age: 60 ± 18). Eleven entire mastectomy tissue specimens from 12patients who underwent 
mastectomy procedure, and all 12 contain malignant tumor. Experiment timeline is shown is 
Figure 6.1. All specimens were immediately immersed in phosphate-buffered saline (PBS) after 
surgery and transported in ice. The small piece specimens used for the experiments were 
approximately 2 cm × 2 cm × 1 cm in size and were received from the department of Pathology at 
CUMC. Small piece specimens were embedded in agar gel matrix soaked in degassed PBS in a 
water tank as shown in Figure 6.2, while the entire mastectomy specimens were directly soaked in 
degassed PBS without embedding. The tank wall was lined with a layer of sound-absorbing 
material to reduce undesired echoes from below.  
 
 
Figure 6.1 Experiment timeline. 




6.2.2 Experiment setup 
HMI measures the vibrational response of the target region to an oscillatory radiation force. 
The radiation force is caused by the change in momentum of the acoustic wave as it propagates 
through a medium. When an AM waveform is used to drive the FUS transducer, the radiation force 
is oscillating at the modulation frequency 𝜔f, which is 25 Hz in this study. In HMI, an oscillatory 
response is induced at the HIFU focal zone due to the AM-HIFU excitation, namely the HMI 
displacement. This HMI displacement can be monitored throughout the entire HIFU treatment 
Figure 6.2 Schematic of Harmonic Motion Imaging (HMI) system with experiment setup. (A) 
Block diagram of HMI system. The red region indicates the focus of the FUS transducer. (B) The 
1D HMI system comprised of a single-element FUS transducer (outer diameter = 80 mm, inner 
diameter = 16.5 mm) confocally-aligned with a single-element pulse-echo transducer (diameter = 
15 mm). (C) The 2D HMI system consisted of a 93-element FUS phase array transducer (outer 
diameter = 110 mm, inner diameter = 41 mm) and a 64-element phase array imaging probe. 
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duration. The change of the peak-to-peak HMI displacement amplitude can be correlated with the 
relative change in local tissue stiffness as the thermal lesion develops. 
A schematic illustration of the main components of the HMI system is shown in Figure 6.2. 
HMI was performed using both 1D and 2D HMI systems in this study. The 1D HMI system 
comprised of a single-element focused ultrasound (FUS) transducer (outer diameter = 80 mm, 
inner diameter = 16.5 mm, center frequency = 4.75 MHz, focal depth = 90 mm. Riverside Research 
Institute, New York, NY) confocally-aligned with a single-element pulse-echo transducer 
(diameter = 15 mm, center frequency = 7.5 MHz, focal depth = 60 mm, Olympus-NDT, Waltham, 
MA, USA) (Figure 6.2). The FUS transducer was driven by an amplitude-modulated (AM 
frequency 𝜔f= 25 Hz) sinusoidal signal generated by a dual-channel arbitrary waveform generator 
(AT33522A, Agilent Technologies Inc. Santa Clara, CA, USA) and amplified by a nominal 50 dB 
gain power amplifier (325LA, E&I, Rochester, NY, USA). The pulse-echo transducer was 
mounted through the center hole of the FUS transducer and confocally aligned with it. It was 
connected to a pulser/receiver (Olympus-NDT, Waltham, MA, USA) operating at 1 kHz. The 
received RF signals from the pulser/receiver were band-pass filtered (Reactel Inc., Gaithersburg, 
Maryland, USA) with cutoff frequencies of fc1 = 5.84 MHz and fc2 = 8.66 MHz and then recorded 
by a digitizer (Gage applied, Lockport, IL, USA) at a sampling frequency of 100 MHz. To generate 
a 3D HMI displacement map, point-by-point raster scan acquisition was used with a step size of 
0.5 mm in transverse plane. At each spot, the FUS exposure varied from 0.1 to 0.6-s long (5 to 30-
cycle oscillations at 50 Hz), during which 100 to 600 RF lines at 1 kHz pulse repetition frequency 
(PRF) were acquired.  
The 2D HMI system consisted of a 93-element FUS phase array transducer (individual 
element diameter = 10 mm, overall outer diameter = 110 mm, inner = diameter 41 mm, center 
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frequency = 4.5 MHz, and focal depth = 70 mm. H-178, Sonic Concepts Inc. Bothell WA, USA) 
and a 64-element phase array imaging probe (center frequency = 2.5 MHz, P4-2, ATL, Bothell, 
WA, USA) (Figure 5.1). In this feasibility study, the 93-element FUS transducer was driven in 
phase using the same function generator and power amplifier as the 1D system. The imaging probe 
was inserted through an opening in the center of the FUS transducer and confocally aligned with 
it. The imaging probe was operated by an ultrasound imaging research system (V-1, Verasonics, 
Bothell, WA, USA). The FUS total output acoustic power was 11 W in 1D system and 8.7 W in 
2D system from radiation force balance measurement [116].   
HMIgFUS ablation monitoring was only performed in 34 small piece specimens, including 
19 normal, 15 IDC and 2 FA specimens using either 1D or 2D HMI system and each specimen 
was ablated at 1-2 different targeted locations depending on the size of the specimen. Prior to 
HIFU ablation, a standard B-mode image of the targeted region was acquired using the imaging 
probe. Then, HIFU was applied for a total duration of 120 s in a single location. Since HMIgFUS 
does not require interruption of HIFU ablation, HIFU sonication was operated with a duty cycle 
of 100%. A customized plane wave imaging sequence was developed using the VDAS (Verasonics 
Data Acquisition System) platform. A GPU-based sparse-matrix algorithm was used for fast 
beamforming [99]. During HMIgFUS exposure, 200 beamformed frames at a frame rate of 1 kHz 
were acquired and transferred to the host workstation every 3 s. An interpolation was performed 
to up-sample the RF signals by a factor of 8 to achieve a sampling frequency of 80 MHz before 
storing the RF signals on the host workstation. After 120 s of continuous HIFU ablation, a total of 
40 date sets were acquired. The main parameters of two systems are summarized in Table 6.1.   
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4.5 MHz 93-element 
FUS phased array 
Imaging  
transducer 
7.5 MHz single-element pulse-
echo transducer 




AM frequency 25 Hz 25 Hz 
Sampling 
frequency 
100 MHz 80 MHz 
Frame rate 1000 Hz 1000 Hz 
Acoustic Power 11 W 8.7 W 
Imaging duration 0.6 s 0.1 - 0.6 s 
Ablation duration 120 s 120 s 
Table 6.1 Main parameters of 1D and 2D HMI/ HMIgFUS systems. 
  
The signal processing techniques were the same for the 1D and 2D HMI systems. Each set 
of continuously acquired RF lines using the 1D HMI system, or each set of the 200 continuously 
acquired RF frames using the 2D HMI system, was processed together. The interference of the 
FUS beam with the RF signals was removed by digital low-pass filtering (fcutoff  =  4 MHz) during 
processing using the 2D system. In the 1D system, the interference of the FUS beam was removed 
by e analog band-pass filter as described previously. The incremental axial tissue displacements 
were estimated by performing a fast 1D normalized cross-correlation between sequentially 
acquired tracking lines [94]. The RF window size was equal to 5 wavelengths of the imaging probe 
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and the window overlap was 95%. A threshold (R2 > 0.7) was applied to eliminate poor 
displacement estimation. The mean peak-to-peak HMI displacement amplitudes and standard 
deviation of the 10-cycle oscillations at 50 Hz were calculated based on the 200-RF lines or frames. 
The aforementioned processing was repeated at each raster scan point to obtain the 3D HMI 
displacement image for breast tumor detection. The range of the ROI was 5mm-diameter circle. 
On entire mastectomy images, a subset of the ROI was manually selected and ROI was located in 
a uniform region of tissue. Signal-to-noise ratio (SNR) is used to assess the quality of images and 
defined as: 
                                                                   𝑆𝑁𝑅 =	 xy                                                                 (6.1) 
Where µ and σ are the mean and standard deviation of the displacement obtained in a homogenous 
region, respectively [137], [138]. 
 
For HMIgFUS ablation monitoring, the mean and standard deviation of the peak-to-peak 
amplitude of the estimated HMI displacements within the ROI were analyzed for the whole 
HMIFU ablation process. To compare among different targeted locations, normalization of the 
HMI displacements by the displacement obtained at t = 2 s was performed. Changes in the HMI 
1. Filter to remove HIFU interference 
2. Estimate axial displacements using 1D 
cross-correlation method 
3. Filter to extract harmonic tissue 
motion at 50 Hz  
4. Calculate the average displacement 
amplitudes and peak-to-peak 
displacement amplitudes 
Acquire RF fames at  
1000Hz during 
imaging and ablation 
   Generate 2D/3D 
HMI 
displacement maps   
Figure 6.3 Schematic of HMIgFUS data acquisition and data processing. 
  75 
 
displacement amplitude were calculated by the percentage change in HMI displacement at the end 
of the thermal treatment over the displacement at t = 2 s.  
A focal spot localization method [114] was used to define the ROI. A maximum peak-to-
peak displacement value was estimated along the axial direction (1D) or the image (2D). Based on 
the maximum peak-to-peak displacement value, we calculated -3 dB displacement focal zone over 
the axial direction (1D) or the image (2D). In order to quantitatively analyze the relative tissue 
stiffness change during heating, the resulting displacement around the focal region was then 
averaged within the -3 dB region. 
3D data rendering (Figure 6.5 B, D and F) was achieved using Amira (VSG, Burlington, 
MA). Matlab (Mathworks, Natick, MA, USA) was used for the statistical analysis. The results 
were presented in mean ± standard deviation format. A paired Student’s t-test was used to 
determine a significant difference (p < 0.05) between before and after ablation. 
 
6.2.3 Histology 
The specimens were kept in 10% phosphate-buffered formalin at low temperature (4 ◦C) 
for at least 24 h. The specimens were then processed and embedded in paraffin, cut in 4-µm-thick 
slices, and stained with hematoxylin and eosin (H&E). 
 
6.3 6.3 Results 
6.3.1 Tumor characterization  
6.3.1.1 Small piece breast specimen 
Figure 6.4 shows the representative B-mode (A) image of a normal breast tissue. Plane 
wave 2D HMI (B, C) were shown within the ROI in (A) marked by dash line. Color in (B) and (C) 
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indicates the amplitude of HMI displacement. (B) shows the peak positive displacement, and (C) 
shows the peak negative displacement. 
 
In Figure 6.5, the 3D HMI images of a normal breast specimen, a breast tumor specimen 





Figure 6.4 Representative B-mode (A) image of a normal breast tissue. Plane wave 2D HMI (B, 
C) were shown within the ROI in (A) marked by dash line. Color in (B) and (C) indicates the 
amplitude of HMI displacement. (B) shows the peak positive displacement, and (C) shows the 
peak negative displacement. 
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Figure 6.5 3D HMI displacement images of normal breast tissue, IDC and FA. (A) Gross pathology 
photograph of a normal breast specimen mounted on the gel matrix, the 3D reconstructed HMI of 
the selected tissue before (B) and after (C) HMIFU ablation. (D) Gross pathology photograph of a 
IDC specimen mounted on the gel matrix, and the 3D reconstructed HMI of the selected tissue 
before (E) and after (F) HMIFU ablation. (G) Gross pathology photograph of a FA specimen 
mounted on the gel matrix, the 3D reconstructed HMI of the selected tissue before (H) and after 
(I) HMIFU ablation. The brighter the color is indicating the higher HMI displacement and lower 
relative stiffness, and vice versa. 
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In the 1D system, the HMI displacement amplitudes of the normal breast, IDC and FA 
averaged within the -3dB regions were 40.10±15.50 µm (n = 9), 24.90±9.64 µm (n = 5) and 7.40 
µm (n = 1), respectively (Fig. 3A); and 24.73±10.97 µm (n = 10), 12.77±10.30 µm (n = 10) and 
2.56 µm (n = 1) with the 2D system (Fig. 3B). Histological analysis found no tissue damage in the 
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Figure 6.6 HMI displacement amplitude on entire mastectomy specimens. (A) HMI displacement 
amplitude on 12 tumors with corresponding surrounding tissue (P < 0.0001). (B) HMI 
displacement contrast ration between tumor and surrounding tissue in comparison with the contrast 
on corresponding B-mode images (P < 0.0001). (C) Image SNR comparison. 
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The mean HMI displacement of the tumor and surrounding tissue were 5.00 ± 2.33 µm and 
13.38 ± 4.94 µm respectively using the 2D system. The mean tumor/surround contrast ration of 
HMI maps and B-mode images were 0.38 ± 0.14 µm and 0.76 ± 0.19 µm respectively.  The SNR 
of tumor and surrounding tissue on HMI maps were 12.59 ± 7.45 and 13.40 ± 8.24 µm respectively.  
And the SNR of tumor and surrounding tissue on B-mode images were 3.72 ± 0.96 and 3.44 ± 
0.54 µm respectively (Figure 6.6).   
 
 
Figure 6.7 Representative B-mode images, HMI displacement maps and HMI displacement maps 
overlaid on corresponding B-mode images on entire mastectomy specimens. 




Figure 6.8 shows both HMI displacement amplitude of the tumor and HMI 
tumor/surrounding ration with corresponding neoadjuvant chemotherapy results. Among the 12 
entire mastectomy specimens, 8 patients did not receive neoadjuvant chemotherapy prior to their 
surgery, and 4 patients received neoadjuvant chemotherapy prior to their surgery. The specimen 
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Figure 6.8 HMI displacement amplitude observation on neoadjuvant chemotherapy. No 
neoadjuvant Chemotherapy (n = 8), no decrease on tumor size after neoadjuvant chemotherapy (n 
= 1), slight decrease on tumor size after neoadjuvant chemotherapy (n = 2) and tumor not grossly 
identified after neoadjuvant chemotherapy (n = 1). 
  82 
 
displacement. And the specimen from the patient whose tumor did not respond to neoadjuvant 
chemotherapy has the lowest displacement. 
 
6.3.2 HMIgFUS ablation monitoring 
Figure 6.9 shows HMI displacement change before and after HIFU ablation using the 1D 
(a) and 2D (b) systems. Tissue motion during heating is visible through the periodic variation in 
displacement amplitude, which is denoted by alternating red (positive) and blue (negative) 
displacement in Figure 6.9. Red denotes highest motion towards the transducer, and blue 
represents highest motion away from the transducer. Using the 1D HMI system, 9 out of 9 (100%) 
normal breast lesions, 5 out of 5 (100%) IDC lesions and 1 out of 1 (100%) FA lesions were found 
to have lower HMI displacement amplitude after HMIFU treatment indicating protein denaturation 
and necrosis. Using the 2D HMI system, 9 out of 10 (90%) normal breast lesions, 8 out of 10 (80%) 
IDC lesions and 1 out of 1 (100%) FA lesions were found to have lower HMI displacement after 
HMIFU treatment. HMI displacement before and after HMIFU ablation were compared by 
performing a paired Student’s t-test. The mean HMI displacement before and after ablation is 
shown in Table 6.2.  
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Figure 6.9 HMI displacement change before and after HMIFU ablation. (A) 9 normal, 5 IDC and 
1 fibroadenoma specimens were imaged with 1D HMI system. (B) 10 normal, 10 IDC and 1 
fibroadenoma specimens were imaged with 2D HMI system. (C) Combined results with both HMI 
systems. * indicates p < 0.05, ** indicates p < 0.001, and **** indicates p < 0.00001. 
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Before After n P value Before  After n P value 
NORMAL 40.10±15.50  17.49±7.85  9 0.0025 24.73±10.97  9.83±6.46  10 0.0048 
IDC 24.90±9.64  12.28±5.44  5 0.0068 12.77±3.50  5.35±2.74  10 0.045 
FA 7.34 6.58 1 
 
2.56 2.06 1 
 
Table 6.2 HMI displacement before and after HMIFU ablation. 
 
 
Percentage of change SD 
Normal -53.84% 25.60% 
IDC -44.69% 29.55% 
FA -15.33% 4.26% 
Table 6.3 Normalized HMI displacement change over the entire HMIFU ablation process. 
 
The mean HMI displacement of the normal breast tissue decreased from 40.10±15.50 µm 
to 17.49±7.85 µm (n = 9, p = 0.0025) using the 1D system, and from 24.73±10.97 µm to 9.83±6.46 
µm (n = 10, p = 0.0048) using the 2D system. The mean HMI displacement of IDC decreased from 
24.90±9.64 µm to 12.28±5.44 µm (n = 5, p = 0.0068) using the 1D system, and from 12.77±3.50 
µm to 5.35±2.74 µm (n = 10, p = 0.045) using the 2D system. The mean HMI displacement of FA 
decreased from 7.34 µm to 6.58 µm (n = 1) using the 1D system, and from 2.56 µm to 2.06 µm (n 
= 1) using the 2D system. A similar decrease was also clearly imaged in 2-D, where the individual 
frameset consisted of peak negative displacement profiles as an example of a treated location. 
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Figure 6.10 HMIgFUS ablation monitoring in 2D overlaying on B mode images in normal breast 
tissue (A) and IDC (B). Tissue motion during heating is denoted by alternating red and blue. In 
red, the motion moving toward the transducer, and in blue represents the motion moving away 
from the transducer. Peak negative HMI displacement frames during a 50-Hz cycle at 5 
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representative time points were selected from the HMIgFUS treatment monitoring sequence to 
show the decrease of focal displacement as the thermal lesion forms. 
 
The normalized HMI displacement change over the entire HMIFU ablation process in all 
specimens is shown in Table 6.3. Compared to the initial displacement at the beginning (t = 2 s), 
the HMI displacement at the end (t = 118 s) of the HIFU ablation was observed. The HMI 
displacement amplitude in normal breast and IDC was 53.84% and 44.69% lower at the end of 2-
min HMIFU ablation compared to those at the beginning of HMIFU exposure, showing consistent 
stiffening after HMIFU ablation. The representative H&E staining results after HMIFU are shown 
in Figure 6.11. Characteristic and similar histologic changes are seen in normal breast parenchyma, 
FA or IDC i.e. all tissues exposed to HIFU. The sections showed discrete hypereosinophilic areas 
reflecting changes occurring in the collagenous stroma as well as cautery like “streaming” 
phenomena in the HIFU ablated epithelial regions. The changes seen in the epithelium/nuclei are 
(non-neoplastic, benign or malignant) reminiscent to what is seen in tissue exposed to 
electrocautery change. Surrounding tissues are histologically unchanged. 
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Figure 6.11 Example H&E staining of HMIFU ablated normal breast (A-C), IDC (D-F) and FA 
(G-I). In A, D and G, scale bar indicates 4 mm; in the rest of the images, scale bar indicates 0.1 
mm. B, E and H are high magnification images of unablated region taken within the corresponding 
black frames, and C, F and I are high magnification images of ablated region taken within the 
corresponding blue frames. The ablated regions show discrete hypereosinophilic areas reflecting 
changes occurring in the collagenous stroma as well as cautery like “streaming” phenomena (arrow) 
in the HIFU ablated epithelial regions. The changes seen in the epithelium/nuclei are (non-
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neoplastic, benign or malignant) reminiscent to what is seen in tissue exposed to electrocautery 
change. Surrounding tissues are histologically unchanged.  
 
6.4 Discussion 
The clinical application of HIFU in tumor treatment is currently hampered by the lack of a 
simple, cost-efficient device to reliably monitor HIFU treatment that can be utilized at the point-
of-care. Experimental HMI images presented in this study demonstrate two important facts: 1) 
HMI is capable of detecting and imaging breast tumors in situ; 2) HMIFU provides the capability 
of monitoring tissue stiffness changes during simultaneously probing and forming lesions within 
the breast tissue.  
It was found that HMI displacement amplitudes in the IDC and FA were on the average 
43% and 85% lower than that in the normal breast, respectively. Although the tissue elasticity 
cannot be directly measured, this displacement contrast ratio can be indexed for relative stiffness 
of different types of tissues in the breast, considering a similar level of radiation force was applied. 
Histological analysis shows that in the setting of low FUS exposure during tumor detection, no 
tissue damage is found, which demonstrates that HMI can be performed without causing tissue 
damage.  
In the entire mastectomy results, the malignant breast tumors have been observed to be 
stiffer than the surrounding tissue and sometimes larger in size in elasticity images than in B-mode 
images. This is consistent with observations in breast elastography [10], [139], [140] and can be 
attributed to the cancer infiltrating the  surrounding tissue which serve to anchor the lesion and 
stiffen the surrounding tissue. One limitation of this study lies in the raster scanning method used 
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in the 2D HMI experiment. Depending on the size of the ROI, a raster scan covering the tumor 
and its surrounding area takes 2-3 minutes. Therefore, it may be subject to motion artifacts induced 
by respiratory motion in patients. Another ongoing study using electronic steering of the FUS 
beam to sweep the focal spot will help facilitate the imaging process. 
Besides tumor detection, HMI offers unique solutions to HIFU tumor ablation monitoring. 
In this study, for the thermal treatment of tumors ex vivo, an acoustic power of 11 W or 8.7 W and 
a duration of exposure of 120 s for each location were used. Significant reduction (53.84% 
decrease in normal and 44.69% decrease in IDC) in the HMI displacement amplitude in the tumor 
after HIFU ablation was observed. This indicates that the HIFU induced lesions could be detected 
through the reduction in the harmonic motion amplitude. HMI monitors the lesion formation based 
on the underlying tissue stiffness changes. Therefore it can be more reliable than monitoring lesion 
formation by tracking the presence of cavitation or boiling bubbles, which are by definition 
stochastic phenomena used currently in the clinic for HIFU treatment monitoring [141]. We 
demonstrated that HMI is feasible for monitoring HIFU ablation in human breast tissue without 
interrupting HIFU treatment.  
Application of HMI for breast imaging and HIFU monitoring is both promising and 
challenging. The overall displacement acquired with the 1D system was higher than that acquired 
with the 2D system due to the acoustic output difference between the 2 systems. It may be due to 
the higher efficiency of the 1D system which generated higher radiation force therefore higher 
displacement in the focal region. The output acoustic power used in the 2 systems were 11 W and 
8.7 W, respectively. Both systems, however, showed similar displacement contrast between 
normal breast tissue, IDC and FA after normalization. Therefore, the power difference in this study 
does not influence the ability of HMI to differentiate abnormal from normal tissues. However, it 
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should be noted that the very low acoustic power output could potentially reduce the SNR with 
depth. Another limitation in this study lie in the raster scanning used in the experiment for 3D HMI. 
It involves a relatively lengthy process and thus will be subject to motion artifacts induced by 
respiratory and cardiac motions when applied in patients. Ongoing studies use electronic steering 
of the FUS beam to sweep the focal spot in order to facilitate the imaging process.  
Furthermore, although off-line processing was used in this study, the 2D HMI system has 
the fundamental capability of on-line monitoring [99]. Ongoing work explores the potential of 
using on-line HMI to provide feedback control of the HMIFU ablation in order to control HMIFU 
therapy. Lastly, 2D HMI clearly located the HMIFU focal region and monitored the stiffness 
change of the focal region over time. However, because of the difficulty involved in sectioning 
through the excised breast to co-register with the imaging plane of the HMI, precise quantitative 
comparisons of actual lesion size and HMI displacement images cannot be performed with 
confidence. To assess the thermal lesion size based on the HMI images, additional studies are 
needed to correlate the HMI displacement map with histological measurements and define a 
quantitative threshold in HMIFU displacement change that corresponds to lesion formation, 
allowing physicians to easily identify the onset of lesion formation. Future studies will also 
consider the correlation between tissue structures and HMI characteristics to better understand 
tissue mechanical responses during HMIFU ablation. 
HIFU has been available in the United States to treat uterine fibroids, prostate tumors and 
relieve pain from bone metastases. Moreover, there is a growing number of clinical applications 
at various stages of research and development around the world, including breast cancer [64], 
pancreatic cancer [35], and brain tumors [142]. MRgFUS has the advantage of high spatial 
resolution with thermometry capability. However, the intrinsic low frame rate of MRI prohibits 
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real-time monitoring of the treatment. On the other hand, USgFUS allows for real-time imaging at 
a relatively low cost. Different from conventional B-mode monitoring which relies on the 
appearance of hyperechoic spots resulting from boiling, HMIFU can provides relative tissue 
stiffness changes in real-time without interfering the HIFU treatment. Future clinical HMIFU 
could thus be used in an outpatient setting. In addition to relatively low costs associated, HMIFU 
will also be characterized by its non-invasive nature and reduced adverse effects. 
The current study laid the foundations for future development of HMI as a clinical 
monitoring technique for breast HIFU with the added capability to detecting tumors for treatment 
planning, evaluate tissue stiffness change during HIFU ablation for treatment monitoring in real 
time, and assess the thermal lesion sizes after treatment evaluation.  
 
6.5 Conclusions and Summary 
In this chapter, we present a noninvasive imaging method for imaging ex vivo breast tumor 
specimens and monitoring of HIFU ablation. Results indicate that breast tumors confirmed with 
pathology can be detected by HMI. HMI has been experimentally shown to be capable of mapping 
and differentiating stiffness in normal and abnormal breast tissues. HMIgFUS can also 
successfully generate thermal lesions on normal and pathological breast tissues.  
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 CHAPTER 7. In vivo human breast tumor characterization using 
Harmonic Motion Imaging (HMI) 
7.1 Introduction 
It has been established that cancer growth results in the alteration of the underlying 
mechanical properties of the breast tissue. In fact, the typical stiffening of tissues as a result of 
breast cancer is usually detected through palpation by the physician and/or self-examination. 
However, as a non-quantifiable diagnostic method, palpation is restricted to detection of tumors at 
locations close to the skin surface while standard techniques, such as mammography and 
sonography, cannot provide the difference in stiffness of the tumors in order to detect them at 
larger depths under the skin surface. Despite its proven high sensitivity, mammography has been 
shown to miss tumors that can be palpated, and is not as efficient in breast cancer screening in 
women below the age of 50. The National Cancer Institute states that the radiation-induced 
mutation can cause breast cancer, especially if exposed before the age of 30 years. Annual breast 
screening is recommended starting at (1) 40 years of age for the general population; (2) 25 to 30 
years of age for carriers of the breast cancer 1 gene and untested relatives of carriers; (3) 25 to 30 
years of age or 10 years earlier than the age of the affected relatives at diagnosis (whichever is 
later) for women with first degree relatives with premenopausal breast cancer or for women with 
lifetime risk for breast cancer 20% on the basis of family history [143]. There is a need to develop 
a highly reliable and low-cost imaging technique for characterization and differentiation tumor 
(begin and malignant) in breast, based on the distinct mechanical property of the tumor that can be 
5-30 times harder than the normal tissues.  
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In this chapter, we propose to investigate the potential complementary role of a novel, non-
ionizing and noninvasive imaging technique, Harmonic Motion Imaging (HMI), which can 
provide measurements of the locally generated mechanical responses and inherent mechanical 
properties of tissues. The result is a new image that contains unique localized information on the 
relative stiffness in and around the tumor. In addition, the vibratory nature of the excitation and 
localized response estimation allows for the direct measurement of tissue hardness. This allows 
for the tumor to be differentiated on the HMI image due to its distinct mechanical properties. The 
HMI technique does not share the requirements of previously developed mechanical methods, such 
as additional acoustical devices, use of external stimulus, or measurement of the response after 
stimulus application. The feasibility of the technique has already been demonstrated on theoretical 
models, tissue-mimicking materials, in vivo animal models and post-surgical human breast 
specimens. When it comes to the clinical translation of HMI, the limitation of the presented system 
in previous chapters lies in two aspects: immobility and relative slow raster scan schematic. The 
studies previously described rely on a 3D positioning system installed on an air table. Nevertheless, 
in a clinical setting where clinicians need to perform treatment localization, monitoring, and 
assessment, it is important to develop a mobile and compact HMI system with the same capability 
to hold and move the transducers precisely. The fast image reconstruction algorithm allows for 
real-time rendering with a temporal resolution of 4.5 Hz [99], [115]. This allows for the tumor to 
be differentiated on the HMI image due to its distinct mechanical properties. This chapter will test 
the initial feasibility on human subjects  
A clinical HMI system will be built with a 4 degree of freedom robotic arm to be able to 
move the transducer precisely for raster scan. For the patients who are planned by their healthcare 
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providers to receive ultrasound-guided breast biopsy, the HMI scan will be performed in the biopsy 
room right before the biopsy procedure.  
 
7.2 Methods 
7.2.1 HMI clinical system 
 
The HMI clinical system (Figure 7.1) consisted of 3 parts: 1) an ultrasound imaging 
research system (Vantage, Verasonics, Bothell, WA, USA) with a designated host PC (Precision 
T7500, Dell Inc., Austin, TX, USA) for system control, real-time display and data acquisition; 2) 
a FUS transducer (fc = 4 MHz, and D = 60 mm, Sonic Concepts Inc., Bothell WA, USA) and a 
phased array imaging probe (a 64-element phased array, fc = 2.5 MHz, P4-2, ATL/Philips, Bothell, 
Figure 7.1 Schematic of 3 major components of HMI clinical system.  
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WA, USA) confocally-aligned through the central opening (diameter = 41 mm) of the FUS 
transducer for imaging and motion tracking; 3) a robotic arm (JACO2, Kinova inc., Boisbriand, 
Quebec, Canada) for automatic raster scan. The robotic arm was mounted on a mobile cart and 
controlled via either a joystick or the PC through a USB cable. The transducer pair was 
mechanically moved using the robotic arm for positioning and point-by-point raster scan as needed. 
In order to synchronize the acquisition of the monitoring signals (i.e., the pulse-echo imaging 
sequence) with the onset of HIFU treatment, the FUS transducer was simultaneously triggered 
with the Verasonics imaging system through a MATLAB-based (Mathworks, Natick, MA, USA) 
custom algorithm on a host PC.  
The channel data signals were individually acquired through a 64-element phased array 
and the Verasonics system using a custom single-transmit based plane-wave wave front imaging 
sequence. The acquisition frame rate was set at 1000 frames/s, the analog-to-digital (A/D) 
sampling was chosen to be 10 MHz which is 4 samples per wavelength at a 2.5 MHz transmitting 
frequency. The acquisition sequence was repeated continuously while the acquired frames were 
transferred in a stacked set of 60 frames through an external function operated within the host PC.  
Additional reconstruction algorithms including beamforming and linear interpolation were 










7.2.2 HMI clinical protocol 
Patient recruitment process was approved by the institutional review board of Columbia 
University, and informed consent was obtained from all enrolled patients. In collaboration with 
the radiology department and the surgery department, patients who were planning to receive 
ultrasound-guided biopsy or breast surgery are eligible, were contacted by study coordinator after 
their office visit. After meeting with the patient and obtaining full consent for our ultrasound study, 
Figure 7.2 HMI data processing. Using lowpass filter to remove the interference from HIFU. 
Low pass filtering: 
Remove HIFU 
interference 
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we planned for HMI scan. The HMI scan was on the day of and prior to their scheduled biopsy or 
surgery. The HMI clinical study did not delay or hinder patient medical care, drug delivery, or 
time to biopsy or surgery. Patients received appropriate standard of care by their diagnostic and 
treating physicians regardless of whether they decide to participate in our study.  
The inclusion and exclusion criteria are: 1) female patients (age > 18 years) with 
symptomatic breast mass which is visible on us; 2) female patients (age > 18 years) with breast 
mass which is invisible on us but palpable; 3) the ideal target lesion upper boundary should be 
within 10 mm from the skin; 4) the ideal target lesion lower boundary should be within 20 mm 
from the skin; 5) exclusion criteria are pregnant or lactating women, women with breast implants 
and women with a history of laser or radiation therapy to the targeted breast. All procedures 
relating to the research study was carried out in a private room. Our ultrasound exam took 15-20 
minutes prior to their scheduled breast biopsy or surgery. Imaging data acquired during research 
procedures was anonymized and encrypted, and immediately removed from the ultrasound 
systems and transferred to the secure endpoint using an encrypted portable hard drive. After the 
transfer is complete, the imaging data was also being removed from the portable drive. 
In the HMI imaging procedure, a B-mode ultrasound image was first obtained using the 
imaging probe only to locate the tumor. Then, a region of interest (ROI) area ranging from 
20x20mm to 60x60mm was be chosen and specified on the PC. Then, a point-by-point HMI raster 
scan with a step size of 2-3 mm was performed within the ROI area to acquired 2D RF data. At 
each spot, the FUS exposure was 0.06 seconds long (3-cycle oscillations at 50 Hz), during which 
60 RF frames at 1000 Hz pulse repetition frequency (PRF) were acquired. The 2D displacement 
data was be saved and reconstructed into 2D HMI image offline.  
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7.3 Results 
7.3.1 Clinical system development 
In order to test the acoustic output of our imaging probe, a standard experimental setup was 
used. The imaging ultrasound probes (P4-2, ATL/Philips, Bothell, WA, USA) was suspended in a 
degassed water bath with the transducers face oriented towards a hydrophone (Onda HGL-0400), 
a highly-sensitive device capable of measuring ultrasound pressures. The hydrophone was 
positioned in the spatial peak of the pressure field, and pressure measurements were digitized and 
saved onto a computer for post-processing. Pressure measurements were recorded for all possible 
output levels. The pressures recorded are related to both the 𝐼𝑠𝑝𝑡𝑎 and MI, which were calculated 
from these measurements. This experiment was performed by two operators, who obtained similar 
results. Having obtained a calibration between output level (2-10V) and acoustic intensity, limits 
were incorporated into the Verasonics user interface. Calibration data is hard-coded in the 
ultrasound scanner, so the user will only be able to apply output levels from 0 to within 90% of 
the FDA limits (𝐼𝑠𝑝𝑡𝑎 of 84.6 mW per cm squared and MI of 1.71). Because two parameters are 
limiting the output, 𝐼𝑠𝑝𝑡𝑎 and 𝑀𝐼, the most restrictive limit will be used as our hardcoded output 
limit.  




In order to test the acoustic radiation force output of our ultrasound system, a standard 
experimental setup similar to that described [144] was used. The 𝑀𝐼 of the pushing beams used 
for HMI imaging was less than the United States Food and Drug Administration limit of 1.9, and 
is consistent with those used in color Doppler imaging. Therefore, the potential for generating 
none-thermal bio effects (i.e., cavitation) with the HMI pushing beams is no greater than that for 
conventional color Doppler pulse sequences with a similar MI. A worst-case estimate of the 
potential temperature increase resulting from the pushing beams used in HMI imaging can be 
estimated by solving the Bioheat transfer equation [145] neglecting convection and conduction 
[146]. Under these assumptions, the equation becomes a first order linear differential equation, 
whose solution provides a linear relationship between temperature increase and application time:  
                                                            𝑑𝑇 = ~W = #4PW 	                                                            (7.1) 
Figure 7.3 Normalized free field focal spot in transvers plane (left) and axial plane (right). 
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where T is the increase in temperature, 𝑞 is the rate of heat production per unit volume, 𝑔 is the 
volume specific heat for tissue, 𝑎 is the absorption coefficient of tissue, 𝐼 is the temporal average 
intensity of the acoustic beam in a given spatial location, and 𝑡 is the application time. For the 
pushing beams used in HMI imaging, the peak anticipated temperature increase in each pushing 
location is 1°C (𝑎	 = 	0.43	𝑁𝑝/𝑐𝑚 at 4.5 MHz), 𝐼	 = 	1000	𝑊/𝑐𝑚# (in situ), 𝑔 = 4.2 3f /°𝐶, 𝑡	 = 	0.01	𝑠). The spatial separation of the pushing locations results in minimal accumulation of 
heat between locations. Thermal increases by less than 1.0°C are considered acceptable during 
diagnostic US scanning [147];and, thus, the HMI push beam sequences used in these experiments 





Figure 7.4 3D rendering of HMI clinical system robotic arm and transducers. 
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7.3.2 Patient results 
From October 2017 to November 2017, 2 patients participated HMI clinical imaging study 
and 1 of the 2 patients had a biopsy after the HMI imaging procedure. The decision to biopsy was 
based on the clinical features, and HMI characteristics were not used to determine biopsy 
indications. HMI acquisition was performed the same day, just before the biopsy. Breast lesions 
from both patients were visible on ultrasound sonography (B-mode). The results from 1 patient 
was not considered due to the technical difficulty encountered during the data acquisition process.  
A representative HMI map is shown in Figure 7.3 obtained from a patient with a known 
fibroadenoma (Figure 7.3 B-mode image shows a hypoechoic mass lesion within the yellow 
dashed rectangle area). The HMI images was taken from the 30x20 mm yellow dashed rectangle 
area denoted in the B-mode image. Normalized tissue displacement plotted in color map where 
blue shows low in displacement and re shows high in displacement. A 5mm-diameter circular 
region of interest (ROI) was chosen within the tumor area and the surrounding tissue with 
displacement amplitude of 1.90 ± 0.40 µm and 3.05 ± 0.60 µm in the fibroadenoma and the 
surrounding tissue respectively.  





Harmonic Motion Imaging (HMI) is a novel imaging technique that applies an oscillatory 
force locally and at different depths in the tissue, in order to determine the characteristics of the 
resulting localized harmonic motion using high precision tracking methods. In this chapter, the 
first HMI system was developed and prototyped for the clinical application of breast tumor 
B-mode 
Normalized HMI map 







HMI displacement map overlaying 
on B-mode 
Figure 7.5 B-mode and HMI map of a patient with a fibroadenoma. The HMI images was taken from 
the yellow dashed square denoted area in the B-mode image. Normalized tissue displacement plotted in 
color map where blue shows low in displacement and red shows high in displacement. 
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characterization. The first HMI clinical trial was designed, proposed and been approved by the 
institutional review board of Columbia University. Chapter 6 has shown that, in ex vivo breast 
specimens, HMI displacement amplitudes in the invasive ductal carcinoma and fibroadenoma were, 
on average, 43 % and 85 % lower, respectively, than that in the surrounding breast tissue. In this 
chapter, we have further optimized HMI method for breast tumor characterization in vivo and 
evaluated of its potential clinical role in detection of breast cancer.  
In comparison with other elasticity based technique, HMI has the advantage of using FUS 
transducer to generate a localized radiation force to probe deep tissue or tumor. Using HMI, highly 
localized harmonic motion can be noninvasively generated by ultrasonic beams deep inside the 
tissue and estimated at high precision, by using RF signals and cross-correlation methods. Due to 
the highly localized and harmonic nature of the response, the motion characteristics can be directly 
linked to the local tissue modulus.  
Despite our successful implementation and feasibility study using the HMI clinical system 
for breast tumor characterization, there are several limitations of the first prototype HMI clinical 
platform. The current prototype requires a water bath for coupling in between the transducer and 
the skin in order to move laterally and axially. In the meanwhile, the raster scan procedure is 
relatively slow due to the mechanical movement. To overcome this limitation, using electronic 
beam steering for HMI as described in Chapter 5 can scan multiple points without mechanical 
movement of the transducer and the water bath is not needed anymore. Using electronic beam 
steering can also significantly increase the imaging speed and shorten the imaging duration from 
the order of minutes to the order of seconds. A FUS phased array is needed with higher number of 
elements and lower central frequency for increased steering range. Another limitation of the 
current HMI clinical system lies in the fact that all images of the 2D acquisition were constructed 
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offline after the imaging procedure. The beam forming and image reconstruction computational 
cost can vary between 5 and 20 minutes, depending on the matrix dimension of the specific raster 
scan, which depends on the tumor size and the ROI area. This hinders the clinical system from 
real-time visualization of the HMI displacement map over the ROI. Therefore, in order to 
successfully translate the first prototype HMI clinical system towards a more clinical friendly 
setting, it is necessary to implement a fast data storage and processing algorithm capable of 
processing displacement, combining raster scan points and streaming real-time HMI displacement 
map back to the user. Boundary conditions may also affect the measurements as they impact the 
oscillation of the tissues probed. The shear wave component resulting from reflection was ignored 
in this study. This assumption is based on the small size of foci (0.25 × 1.25 mm2) compared to 
the size of tumor, and the fact that our measurement is confined to the focal region.  
The preliminary results shown in this chapter indicate that HMI can may be an additional 
tool for breast tumor detection and localization, it may also be used as a technique to assess 
chemotherapeutic response during such therapy. This mechanical effect of chemotherapy was 
previously observed in breast cancer by Falou et al. [148]. In this study, 15 women received 
neoadjuvant chemotherapy and were monitored using elastography for 8 weeks. Responders 
demonstrated a significant decrease in mechanical properties 4 weeks after treatment initiation 
compared to non-responding patients. Moreover, elasticity imaging has shown interesting potential 
to predict response to neoadjuvant therapy in breast cancer [149]–[151] demonstrating the different 
uses of elasticity assessment for cancer therapy. 
The study in this chapter has laid foundation for the development of a clinical Harmonic 
Motion Imaging guided Focused Ultrasound (HMIgFUS) system for breast tumor treatment and 
monitoring. HMIgFUS is an all-ultrasound-based non-invasive treatment technique with added 
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capability of real time treatment monitoring, which can be used to investigate the underlying local 
tissue mechanical property without stopping the HIFU treatment.  
 
7.5 Conclusions and Summary 
The first HMI clinical system has been built with a robotic arm for fast raster scan with 
added capability of GUP-based parallel beamforming. A clinical trial has been approved to image 
breast tumor on patient with breast mass. The HMI clinical system has shown to be able to map 
fibroadenoma mass on one patient with valid HMI displacement consistent with previous ex vivo 
studies. This imaging technique is a non-ionizing, noninvasive, and low-cost imaging technique 
compared to currently available methods. The study in this chapter may yield an assistive 
diagnostic technique for breast cancer providing further information on the relative stiffness of the 
tumor without any age discrimination. This chapter also lays foundation for future development of 
a clinical HMIgFUS system with the added capability of treatment planning, treatment monitoring 
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 CHAPTER 8. Conclusion summary and future works 
8.1 Conclusion & summary 
The scope of this dissertation has been focused on the system optimization, prototyping 
and clinical feasibility testing of a biomechanical assessment and monitoring of thermal ablation 
using Harmonic Motion Imaging guided Focused Ultrasound (HMIgFUS) for the application of 
breast tumor. 
In Chapter 3, a new HIFU treatment planning method was described that used oscillatory 
radiation force induced displacement amplitude variations to detect the HIFU focal spot before 
lesioning. This method was applied on tissue-mimicking phantoms and in vitro tissues with both 
the 1D and 2D tracking HMI systems. Using this method, we were able to visualize the HMIgFUS 
focal region at variable depths before applying HIFU treatment. By comparing the estimated 
displacement profiles with the actual lesion locations in pathology, we demonstrated the feasibility 
of using this HMI-based technique to localize the HIFU focal spot and predict lesion location 
during the treatment planning phase of a successful HIFU treatment. The same application 
feasibilities were also demonstrated in a 2D preclinical system. We concluded that HMI has the 
potential of providing the capacity for HIFU planning.  
In Chapter 4, A HIFU lesion detection and ablation monitoring method was developed 
using oscillatory radiation force induced displacement amplitude variations in real time. 
Performances were assessed in vitro in canine liver, and in vivo initial feasibility was shown in a 
mouse pancreatic tumor model. Using this method, the HMIgFUS focal region and lesion 
formation were visualized in real time at a feedback rate of 2.4 Hz. By comparing the estimated 
lesion size against gross pathology, we demonstrated the feasibility of using HMIgFUS to monitor 
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treatment and lesion formation without interruption during the treatment monitoring phase of a 
successful HIFU treatment. We concluded that HMIgFUS has the potential of providing the 
capability for real-time HIFU monitoring.  
In Chapter 5, it was shown that using the steered FUS beam using a 93-element phase-
array FUS transducer, HMI can be used to image a 2.3 times larger ROI without physical 
movement of the transducer. Using steering for HMI can be used to shorten the total imaging 
duration without requiring physical movement of the transducer. The main limitation of this study 
lies in the design of the FUS transducer, which constrained the effective steering range of the FUS 
beam to +/-1.7 mm and +/-2 mm in the lateral and axial direction.  
In Chapter 6, HMI and HMIgFUS were optimized and applied to ex vivo human breast 
tissue. A noninvasive imaging method for imaging postsurgical breast tumor specimens and 
monitoring of HIFU ablation was presented. The results showed that HMI is experimentally 
capable of mapping and differentiating stiffness in normal and abnormal ex vivo human breast 
tissues. HMIgFUS can also successfully generate thermal lesions on normal and pathological 
breast tissues. HMI has also been applied to post-surgical breast mastectomy specimens to mimic 
the in vivo environment.  
In Chapter 7, the first HMI clinical system was reported with added capability of GUP-
based parallel beamforming. A clinical trial has been proposed and approved at Columbia 
University to image breast tumor on human subjects. The HMI clinical system has shown to be 
able to map fibroadenoma mass on one subject with valid HMI displacement consistent with 
previous ex vivo studies. The study in this chapter may yield an early-detection technique for breast 
cancer without any age discrimination and thus, increase the survival rate. This imaging technique 
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is a non-ionizing, noninvasive, and low-cost imaging technique compared to currently available 
methods.  
 
8.2 Future directions 
In order to build an integrated, all-ultrasound-based clinical HIFU system for breast cancer 
with the added ability of tumor characterization, there are improvement need to work on the three 
stages: 1) Treatment planning, 2) Treatment monitoring, and 3) Treatment Assessment.  
For the treatment planning stage, a user friendly interactive interface needs to be built for 
tumor localization. With the interface, the physician is able to outline the breast mass on 
consecutive sections of B-mode scans and HMI displacement maps in order to the position of the 
focal zone relative to the breast mass center. Thereafter, the number of treatment units and the time 
for treatment will be automatically calculated to cover the target volume with extra margin of 
normal tissue. A Systematic review [34] of HIFU ablation in the treatment of breast cancer 
including 9 studies has found the extra margin of normal tissue ablated around the target tumor in 
the included studies varied from 0.5 to 2 cm. The two studies [133], [152] with a margin of between 
1.5 and 2 cm are the only two to report complete necrosis of the lesion in all patients, and both 
used ultrasound-guided HIFU therapy. In order to achieve complete necrosis of the lesion in all 
patient, a margin of 1.5 - 2 cm will be used in our study. 
In treatment monitoring, ongoing efforts will focus on designing a FUS transducer with 
more elements and lower center frequency to enlarge the effective steering range for HMI. The 
feasibility of using electronic steering for HMIgFUS has been proven in Chapter 5 as it facilitates 
both HMI and HMIgFUS process by electronically steering the focal spot to several different 
predetermined locations. Using electronic steering can significantly increasing the 
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imaging/treatment area and shortening the imaging duration without physical movement of the 
transducer. However, the current steering range is limited by the design of the current FUS 
transducer. Therefore, designing a FUS transducer with more elements and lower center frequency 
can effectively enlarge both axial and lateral steering range for HMI. Other ongoing efforts include 
the on-line HMI focal spot localization to provide real-time feedback control to reduce treatment 
time and to enhance ablation accuracy during the HIFU treatment. Real-time feedback control 
algorithms for HIFU therapy based on pulse-echo ultrasound imaging have been tested in previous 
research [153]–[156]. Curiel et al. evaluated the feasibility of using localized HMI to monitor and 
control HIFU ablation in a rabbit tumor model. The treatments were automatically stopped if the 
detected localized harmonic motion amplitude at the focal spot dropped below a specified 
amplitude threshold in two consecutive measurements. This algorithm was able to successfully 
control ablation in 69% of the trials [154]. Using the real-time lesion detection and ablation 
monitoring method (Chapter 4), lesion size monitoring was achieved and lesion formation were 
visualized in real time at a feedback rate of 2.4 Hz. It also laid foundation for a real-time feedback 
control system based on the estimated lesion size growth curve. The treatments should 
automatically stop if the estimated lesion size is shown to not increase in size or the growth rate is 
under a set threshold. 
From the system aspect, HMIgFUS can be integrated into commercial HIFU systems, such 
as the Theraclion Echopulse system (Figure 8.1). It has shown capability to effectively treat thyroid 
nodule with proven of macroscopic and microscopic histological examinations of thyroid tissue 
removed during surgery [32]. Echopulse is also in clinical trial overcome the prolonged treatment 
duration in benign breast tumor by applying HIFU pulses to the circumferential surface area rather 
than the whole volume with ultrasound B-mode guidance [157]. In another clinical trial, twenty 
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female patients diagnosed with palpable, non-calcified breast fibroadenomas 1cm or larger are 
enrolled in a single arm clinical trial and undergo HIFU treatment using the Echopulse system 
[158]. The Echopulse is equipped with a linear array imaging transducer (number of elements 
= 128, center frequency = 7.5 MHz) confocally-aligned with the focused ultrasound transducer to 
acquire B-mode images from the target area.  This transducer is designed by Theraclion for the 
application in thyroid and breast, and has shown to be able to provide high quality B-mode images 
from 40 mm distance from the skin. This phased imaging array will also satisfy the imaging 
application in mice with sufficiently high in resolution due to the high center frequency. The HIFU 
and imaging frequencies are sufficiently distinct to effectively filter out the HIFU spectrum. Their 
clinical HIFU system will be programed to perform HMIgFUS in the Visualization and Treatment 
Unit (VTU) using their research platform that provides full control over the beamformer and 
overall programming in addition to the robotic arm. The imaging transducer can be operated by an 
open-architecture system (Vantage, Verasonics, Redmond, WA). 
To test the feasibility of using Theraclion Echopulse for HMI, a Visualization and Treatment 
Unit (VTU) from the Echopulse system was modified to connect to an ultrasound imaging research 
system (Vantage, Verasonics, Bothell, WA, USA) to track the displacement in conjunction with a 
HIFU transducer as shown in Figure 8.3 shows the focal area and displacement over time detected 
by VTU on the in vitro liver specimen.  
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Figure 8.2 HMI feasibility test with Thercalion Echopulse VTU connected to a Verasonics system. 




Figure 8.3 (Left) Theraclion VTU acquired HMI peak-to-peak displacement in liver specimen. 
(Right) Theraclion VTU acquired HMI displacement over time. 
 
With the development of high-frequency ultrasound imaging array, the usefulness of high-
frequency ultrasound as a tool for diagnosis has been evaluated in clinic. High-frequency 
ultrasound elastography (8 - 40 MHz) has been used to assess cutaneous melanoma in human 
subjects [159]. HMI, as an elasticity-based imaging technique, will also benefit from high-
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